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1. Introduction 
1.1 The immune system 
The immune system is a complex of mechanisms and structures which protects an 
organism from infectious agents and pathologic processes. The disease can be 
caused by pathogens, like viruses, bacteria, fungi, but may be also caused by 
internal mechanisms, like autoimmunity or cancer. Protection in invertebrates is 
provided by an innate immune system, whereas vertebrates have developed an 
additional, adaptive immune system, which can provide a specific immune response 
against a pathogen. 
 
1.1.1 The innate immune system 
The innate immune system represents first line of immune response and becomes 
immediately activated after an organism is invaded with a pathogen. The 
mechanisms of innate immune system are not specific to a certain pathogen. They 
can be recognized by molecular structures, called pathogen associated molecular 
patterns (PAMPs). The parts of the innate immune system include: molecular 
(antimicrobial compounds), cellular (macrophages and neutrophils) and more 
complex (skin). The innate immune system can be further subdivided into four types 
of defense: anatomical barriers, physiological barriers, phagocytosis and 
inflammation. (99) 
 
1.1.1.1. Cellular components and function of the innate immune response 
 
The development of immune response occurs in bone marrow and leads to formation 
of different immune cells. PAMPs are recognized by pattern recognition receptors 
(PRRs) and these molecules can either be soluble or cell-associated. Examples of 
PRRs are the macrophage mannose receptor, complement, toll-like-receptors (TLRs) 
nucleotide-binding oligomerization domain receptors, cytoplasmic RNA sensors like 
RIG-I and MDA-5 (recognizes dsRNA) and cytosolic DNA sensors like cGAS 
(recognizes dsDNA) (2, 99). These receptors trigger various responses, like 
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phagocytosis, chemotaxis, and upregulation of co-stimulatory molecules or secretion 
of cytokines (2, 99).  
Natural killer (NK) cells are a part of the innate immune response. They are able to 
respond to pathogens immediately in a non-specific manner. When activated, NK 
release of cytotoxic granules, containing granzymes (Gzm) and perforin. This leads 
to the induction of apoptosis in the target cells. NK cells express ligands for death 
receptors like TRAIL (tumor-necrosis factor-related-apoptosis-inducing ligand) or 
FasL, which kill cells through binding to their receptors on the target cells. (99) 
Phagocytosis is another feature of the immune system, which is performed by 
specialized immune cells, such as dendritic cells (DCs) macrophages/monocytes,  
and granulocytes (especially neutrophils). These cells can destroy pathogens in 
phagosomes. Monocytes (in the blood) or macrophages (in tissues) are long-lived 
phagocytic cells which secrete signaling proteins like cytokines and chemokines to 
attract other immune cells. Activated macrophages initiate the process of 
inflammation.  Additionally, DCs can take up large amounts of extracellular fluid and 
its content (macropinocytosis). Their main function is the recognition and degradation 
of invading pathogens. DCs present antigens within the major histocompatibility 
complex (MHC) molecules on their surface to naïve T lymphocytes. The first 
encounter happens in peripheral lymphoid organs to initiate the adaptive immune 
response. DCs are also able to produce cytokines that influence the innate and 
adaptive immunity. The mechanism of antigen presentation provides the crucial 
connection between innate and adaptive immunity and is essential to initiate an 
effective immune response against a pathogen (2, 99). The innate immune response 
provides the first and quick defense against foreign structures. Components of innate 
immunity may be divided in natural and mechanical barriers (e.g., skin, surface 
epithelia, cilia), chemical protection (e.g., proteases, lysozyme), the complement 
system, which are both humoral and cellular units (99).  
 
1.1.1.2 Humoral components of the immune system 
The humoral immune response consists of different soluble factors, such as 
complement and cytokines. Complement system is an  enzymatic cascade of 
different proteolytic enzymes. This system consists of opsonization, local 
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inflammation, chemoattractant or by binding the pores on the cell membrane in order 
to destroy the cell (99). 
Cytokines are various soluble, immunoregulatory factors, such as interleukins (IL), 
interferons, colony stimulating factors, chemokines, and tumor necrosis factors. 
Cytokines are the key factors in the cell-cell communication and affect cell growth, 
migration, development, differentiation and apoptosis of cells. They have an 
important function as signaling molecules during the tumor development and are 
important for the tissue damage repair (2, 99). They also modulate the immune 
response, control the virus replication and thus contribute to an effective immune 
response (99). One of these groups is interferons, (IFN), which can be induced as a 
result of PRR stimulation by its ligand resulting from different infections. Type I 
interferons (IFNα and IFNβ) are important players in the immediate anti-viral 
response. Almost all cells express the interferon receptor. Upon binding of its ligand 
an anti-viral state is induced, which is characterized by the expression of hundreds of 
interferon stimulated genes that are able to reduce viral replication and modulate 
immune cell responses (2, 99). 
 
1.1.1.3 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) is a heterogeneous population of 
activated, immature myeloid cells, which show robust suppressive function. First, 
these cells was described around 30 years ago (150), but only lately got deserved 
attention due to evidence about suppressive function in distinct models, such as 
cancer (59), infectious diseases (HBV, HCV, HIV), autoimmunity etc.. 
Myeloid-derived suppressor cells are characterized in different models, both in vitro 
and in vivo. In murine model they are defined by co-expression of Gr1 (which 
consists of 2 epitopes Ly6G and Ly6C) and CD11b (αM-integrin). In healthy, murine 
bone marrow, cells with this phenotype take 20%-30% of cell suspension. Spleen 
contains only small amount of MDSCs, around 1-3%, of Gr1+ CD11b+ cells. MDSCs 
are absent in lymph nodes. MDSCs are, in mice, divided in two distinct populations: 
granulocytic or polymorphonuclear (gMDSCs) and monocytic (mMDSCs). gMDSCs 
are characterized with expression of CD11b+ and high expression of Gr1, or as 
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CD11b+ Ly6G- Ly6C+ cells. This population shows morphological and phenotypical 
similarities to neutrophils. Monocytic MDSCs morphologically and phenotypically 
resemble monocytes. mMDSCs are defined by expression of CD11b+ and dim 
expression of Gr1 or as CD11b+ Ly6G- Ly6C+ cells. 
 
 
 
Figure 1.1 Murine granulocytic and monocytic MDSCs 
Murine MDSCs consist of two main subsets with distinct functions: granulocytic and 
monocytic. gMDSC suppress the T cell response mainly via ROS and arginase activity, and 
mMDSCs the T cell response via NO and arginase.      
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In human system, MDSCs are mainly characterized by expression of the common 
myeloid marker CD33, CD11b, and lack of CD14 expression. They also not express 
maturation markers for myeloid and lymphoid cells, as well as MHC-class-II molecule 
HLA-DR. CD15+ is also used for characterization of MDSCs in peripheral blood. 
PBMCs of healthy individuals contain mostly ~0.5% of cells with this phenotype. (59) 
MDSCs are generated from common myeloid progenitor cells in bone marrow (BM). 
This process is regulated by series of signals, which may be divided into two 
categories: promotion of accumulation of immature myeloid cells, and provision for 
the pathological activation of these cells.  
 
1.1.1.4 Mechanisms of MDSCs suppressive activity 
MDSC action is conducted either though cell-cell contact or is mediated though 
soluble factors.  
MDSC suppressive activity is historically associated with ι-arginine metabolism. In 
this processes ι-arginine may by converted by two enzymes: arginase-1 (ARG1) and 
inducible nitric oxide synthase-2 (iNOS or NOS2). In first process ι-arginine is 
metabolized by ARG1 into urea and ι-ornithine, while NOS2 converts it into nitric 
oxide (NO) and ι-citrulline. MDSCs are expressing high levels of these enzymes, due 
to exposure to specific cytokines, where Th2 cytokines TGF-β and IL-10 and 
associated with ARG1, and Th1 cytokines IFNγ, IL-1, IFNα and TNFα with NOS2. 
High activity of these enzymes was shown to inhibit T cell function through distinct 
mechanism. (21, 141)  
High MDSCs related arginase activity leads to arginine depletion from 
microenvironment, which absence leads to decreased expression of T cell-CD3ζ, and 
through this unable transmission of signal for T cell activation. It may also suppress 
the cell cycle regulatory protein cyclin D3 and cyclin-dependent kinase 4, which is 
shown to block proliferation of T cells (111).  On the other hand NOS2 mediated 
production of NO by MDSCs may interfere with JAK/STAT signaling proteins, 
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required for distinct T cell functions, suppress MHC II expression and induce T cell 
apoptosis. (21, 59, 84, 149)  
Described above mechanism are ι-arginine dependent. The other mechanisms 
involved in MDSCs mediated suppression, such as reactive oxygen species (ROS) 
production, TGF-β production, cysteine depletion, CD62L downregulation, are ι-
arginine independent (141).  
Another important function of MDSCs mediated immune suppression is reactive 
oxygen species (ROS) production. Increased production of ROS is one of the 
characteristics of MDSCs. The increased ROS production by MDSC is mediated by 
up-regulated activity of NADPH oxidase (NOX2). Inhibition of ROS production by 
MDSCs in murine and human model efficiently abrogated suppressive effect of 
MDSC in vitro. Interestingly, the interaction of T cells with MDSCs was shown to 
increase ROS levels due to ligation of integrins expressed on the surface of MDSCs. 
The production of ROS by MDSCs may be further induced by several known tumor-
derived factors, such as TGFβ, IL-10, IL-6, IL-3, platelet-derived growth factor 
(PDGF) and GM-CSF.(141)  
 
1.1.1.5 Immune regulation and depletion of MDSCs 
 
Different attempts to study the function of MDSCs in vivo have been proposed. First, 
transfer experiments were performed, in which freshly isolated, lipopolisaccharid 
(LPS) or IFNγ induced MDSCs were transferred into recipient mice. This attempt was 
shown to inhibit inflammation (147) and reduce CD8+ T cell responses in a 
melanoma model (128). Another approach to study the function of MDSCs in vivo is a 
specific depletion of these cells. There are different ways to modulate MDSC by 
reduction of numbers or blockade of the function of MDSCs in vivo. The most 
commonly used way of depletion is by administrating αLy6G or αGr1 antibodies into 
mice. This procedure allows the efficient depletion of all MDSCs (αGr1 antibody) or of 
granulocytic MDSCs only (αLy6G antibody). Nevertheless, as lately shown, long term 
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administration of either αGr1 or αLy6G antibody leads to reappearance of immature 
Ly6G+ cells (45).  
The modulation of immune responses offers promising results for the therapy of 
different diseases, including cancer and viral infections (91, 144).  
Different methods were described to deactivate (influencing MDSCs accumulation by 
TLR agonists) or deplete MDSCs (depletion by 5-Fluorouracil), as well as 
differentiate them into mature cells (maturating granulocytic MDSCs by ATRA) or 
block their development (144). Many of these agents, like 5-Fluorouracil (5FU), 
ATRA, PDE-5 inhibitors, NO-aspirins, CSF-1R inhibitors, Zoledronic Acid, 
JAK/STAT3 inhibitors and Multi-Kinase inhibitors, as well as VEGF inhibitors, are 
already under clinical investigation in cancer treatment (91, 144).  
5-FU is an analog of uracil, anti-cancer drug, which operates as antimetabolite by 
inhibiting thymidylate synthase. 5FU selectively deplete MDSCs. The 5FU what leads 
to increased IFNγ production by tumor-specific CD8+ T cells.  
An overview of different strategies used for MDSC immunomodulation is presented in 
Table 1.1. 
  
Table 1.1 Strategies of MDSC inhibition under investigation (144) 
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1.1.2. The adaptive immune system 
While the innate immune response is activated within hours, it takes days to weeks 
for the adaptive immune system to develop its protective effects. Adaptive immunity 
is different to innate immunity in the way that it is pathogen specific, it takes time to 
develop and a memory response can be launched at second encounter with an 
antigen. The adaptive immune system can be divided into the cellular (T and B cells) 
and humoral (antibodies) components. Recognition of invading pathogens by DCs 
leads to their activation, causing the upregulation of MHC class I and class II, as well 
as co-stimulatory molecules to initiate an effective T cell response. After migration to 
lymphoid organs, DCs present nonself- peptides bound to MHC molecules on their 
surface to naïve CD4+ and CD8+ T cells. CD4+ T cells only interact with peptide 
bound to MHC class II and CD8+ T cell only recognize peptides bound to MHC class 
I. Whereas almost all nucleated body cells express MHC class I, MHC class II is only 
present on professional antigen presenting cells (APCs), like DCs. There are two 
different pathways that lead to the presentation of a peptide on an MHC molecule. 
Peptides presented on MHC class I molecules are of cytosolic or endoplasmic 
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reticulum (ER) origin, whereas peptides presented on MHC class II molecules are 
derived from endosomes. All peptides are usually of pathogenic origin and the result 
from different routes of infection or pathogen encounter. For MHC class I loading 
endogenous antigens are generated. These are derived from misfolded proteins of 
cellular or pathogenic origin, or proteins produced within an infected cell. These 
proteins are cleaved into smaller peptides by the proteasome. The unloaded MHC 
class I molecule is initially located in the luminal side of the ER membrane. 
Therefore, peptides must be transported into the ER lumen via the transporter 
associated with antigen processing (TAP). TAP has the highest affinity for peptides 
with a length of 8 to 10 amino acids and with hydrophobic and basic carboxy-terminal 
amino acids, which present the optimal size and anchor charge for MHC class I 
binding. The process of MHC class I:peptide-complex assembly is highly chaperone 
guided. The fully assembled complex is then transported to the surface of the cell via 
the Golgi apparatus, where it can be recognized by specific CD8+ T cells. (99) MHC 
class II loading occurs in a different process with peptides derived from exogenous 
antigens captured through phagocytosis or endocytosis. The internalized antigens 
become degraded in increasingly acidified compartments (early endosome – 
endolysosome – lysosome) containing hydrolytic enzymes. In this process 
oligopeptides with a length of 13 to 18 amino acids are produced, which are able to 
bind to the peptide binding groove of the MHC class II complex. The assembly of the 
two chains of the MHC class II complex takes place in the ER, where an invariant 
chain blocks the peptide binding groove from binding endogenous peptides and 
stabilizes the complex. After passing through the Golgi apparatus, the MHC class II: 
invariant chain-complex is included in the endosomal-lysomsomal pathway. The 
invariant chain is degraded, leaving only a small fragment blocking the peptide 
binding groove (CLIP, class II-associated invariant chain peptide). In a chaperon-
mediated pathway, the CLIP is released and replaced by a peptide produced from 
the endosomal-lysosomal pathway. The MHC class II:peptide-complex is then 
presented on the surface of APCs, where it can be recognized by specific CD4+ T 
cells. (79, 99) 
B cells are APCs and thereby able to activate naive CD4+ T cells. Their principle role 
is in the production of antibodies, as part of the humoral immune response to 
pathogens. B cells mature into antibody-producing plasma cells and memory B cells 
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in an antigen-driven way. B cells can be activated in two different ways: by thymus 
independent antigens and thymus-dependent antigens, which is mediated with the 
help of CD4+ T cells. In response to stimulation, B cells produce antibodies and this 
process can be divided into primary and secondary responses. In the primary 
response, naïve B cells become activated to produce antibodies, whereas in the 
secondary response, plasma cells are activated to produce more specific antibodies 
of different classes. These antibodies from the secondary response are more specific 
because the B cells have undergone clonal selection, expansion and differentiation in 
germinal centers. Antibody production is important for specific pathogen recognition 
and elimination (complement activation, opsonization and neutralization of pathogens 
and phagocytosis of pathogens). (99) 
 
1.1.2.1 Effector CD8+ T cells 
CD8+ T cells, also called cytotoxic T lymphocyte (CTL), are a subset of T 
lymphocytes, showing effector function. To achieve their function cytotoxic cell CD8+ 
T cell acquire activation. To achieve this naïve CD8+ T cell need to recognize antigen 
peptides presented by MHC Class I molecule on activated antigen presenting cells 
(APCs). MHC I molecules are present on all nucleated cells and present epitopes of 
viral peptides. CD43 and CD62L are the two glycoproteins used for identification of 
cytotoxic T lymphocytes. The CD62L molecule is the adhesion and homing receptor, 
it derives naive T cells through interaction with endothelial cells to secondary 
lymphoid organs. In case of an encounter of the naïve T cell with its specific antigen 
the expression of the cell surface molecule CD62L is downregulated. Lack of 
expression of CD62L classifies the CD8+ T cell as activated CD8+ effector cell [100, 
101]. After activation the CD8+ T cells play a role not only in the elimination of 
infected cells, but they also secrete different cytokines (e.g. IFN-γ, TNF-α) and 
chemokines and thus also have a regulatory character (99). Cytotoxic CD8+ T cells 
can kill infected cells by exocytosis of lytic granules, as for example, proteases 
(granzyme), lytic enzymes such as perforin or cytokines (IFN-γ, TNF-α, etc.), or 
TRAIL (CD253) / TRAIL receptor and Fas (CD95) / Fas (CD95L) mediated apoptosis. 
During a primary immune response CTLs expand over several hundred folds and 
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form a very efficient antigen-specific effector immune response and are able to kill 
several target cells (15). 
Cytotoxic CD8+ T cells maintain their function by several cellular mechanisms or 
secreted molecules. After forming immunological synapse with target cell, CTL may 
act on two distinct ways: calcium dependent or calcium independent. First and 
principal of them, is the calcium-dependent secretion of cytotoxic granules, such as 
granzymes and perforins, upon antigen recognition.  
Gzms are serine proteases that are stored in specialized lytic granules of CTLs and 
NK cells along with perforin. In mice, ten Gzms (A-G, M and gene duplications) and 
in humans five Gzms (A, B, H, K and M) have been described. When CD8+ T cells 
become activated and recognize their antigen in an MHC class I context, these 
granules can be released and the Gzms can kill the target cell. For the Gzms to enter 
the target cell, perforin pores are formed in the target cell membrane in a calcium 
dependent manner. Upon entry into the target cell, Gzms induce proteolytic cleavage 
of caspases eventually leading to DNA fragmentation and cell apoptosis. In addition 
to activating caspases, Gzms can also activate caspase-independent mitochondrial 
collapse, resulting in the release of cytochrome c, a pro-apoptotic protein (24, 99). 
 
The Fas (CD95) – FasL (CD95L) pathway is another pathway through which CTLs 
can induce apoptosis in target cells. Fas is a member of the TNFR family and 
contains an intracellular death domain to deliver an apoptotic signal upon FasL 
binding. Fas expression is induced by TNFα and IFNγ or the activation of 
lymphocytes and FasL is expressed after TCR engagement on CD8+ T cells. The 
activation of the Fas – FasL pathway results in the activation of caspases and leads 
to apoptosis (154).  
In addition to the above mechanisms, cytokines like IFNγ and TNFα are secreted by 
activated CD8+ T cells. It should, however, be noted that these cytokines can be 
secreted by a variety of other immune cells as well (T cells, NK cells, APCs). IFNγ is 
the only member of the type II interferons with a wide range functionality, like: 
leukocyte attraction, maturation and differentiation of many cell types, NK cell activity 
enhancing action and regulation of B cell functions and altering macrophage function 
during infections. IFNγ also up-regulates factors involved in CD4+ T cell recognition 
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and induces further MHC class II expression on APCs and other cells. IFNγ is also 
involved in the up-regulation of MHC class I and the immunoproteasome, therefore 
providing efficient recognition of virus-infected cells by CTLs. It also elicits direct 
antiviral effects by regulating antiviral proteins (induces an antiviral state) and has 
pro-apoptotic and anti-proliferative effects (45, 99). 
The surface expression of CD107a (lysosomal-associated membrane protein-1) is a 
way to determine if cells recently de-granulated. CD107a is located on the surface of 
intracellular granules designated for exocytosis. Upon degranulation of these 
intracellular bodies CD107a becomes exposed on the cell surface until it is recycled 
(99, 119). 
 
1.1.2.3 The different CD4+ T cell subsets  
After activation and several rounds of division naïve CD4+ T cells differentiate into 
various CD4+ T helper subsets. The function and effector or helper mechanism of the 
CD4+ T cell response is dependent on the cytokine milieu. The best described 
subsets are Th1 and Th2 cells, which are characterized by strong IFNγ or IL4 
production, respectively. Th1 cells activate macrophages and drive inflammation and 
Th2 cells induce an effective humoral antibody-mediated immune response. In a viral 
infection, the Th cell response consists mainly of Th1 cells, where they are important 
for enhancing the CD8+ T cell responses and memory cell development. Many 
different Th subsets have been described, like T follicular helper cells (Tfh) 
(specialized B helper cells), Th17 (pro-inflammatory), Th22 (potentially involved in 
skin homeostasis and pathology), cytotoxic CD4+ T cells (mediating direct killing) and 
induced regulatory T cells (iTreg) (immunosuppressive). Th cell subsets have a 
certain level of plasticity and can convert under special change of cytokine milieu into 
other Th subsets (99).  
1.1.2.3.1 T regulatory cells 
Tregs are specialized subpopulation of CD4+ T cells, which are naturally present in 
the immune system. Normally 10-15% of CD4+ T cells in mice are Tregs. The main 
function of Tregs, also known as suppressor T cells, is to maintain immune 
homeostasis (99). Like other T cells, one subset of Tregs matures in the thymus 
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where they are characterized by the expression of CD4, CD25 and Foxp3. These are 
the natural Tregs. Natural Tregs express IL-2Rα chain (CD25) and the transcriptional 
repressor forkhead box protein 3 (Foxp3). Natural Tregs are characterized by 
selective, surface expression of Neuropilin-1 (Nrp-1) (85). Tregs that arises in the 
periphery are called inducible Tregs. This cell population is generated from naïve 
CD25+ or CD25- T cells in the periphery upon antigen presentation by semi-mature 
DCs and under the influence of IL-10, transforming growth factor β (TGF-β) and 
possibly IFN-α (63).  Higher numbers of CD4+ Tregs in cancer patients compared to 
normal healthy controls have been reported in recent in head and neck, 
hepatocellular, gastric, breast, ovarian, lung, melanoma, renal cell, and pancreatic 
cancer (150). Increased numbers of Tregs have also been observed in numerous 
human and animal studies of chronic viral infections, in Hepatitis C virus (HCV) (91), 
HIV (17) and herpes simplex virus (HSV) (131) infections. There are four suppression 
mechanisms, which are utilized by Tregs. Tregs can secrete inhibitory cytokines, 
such as IL-10, TGF-β, and IL-35, and apply these soluble factors as a main 
mechanism of suppression. Recent studies showed that Tregs may use 
perforin/granzyme-mediated cytotoxicity. Metabolic disruption by Tregs includes high-
affinity CD25 dependent cytokine-deprivation-mediated apoptosis, cyclic adenosine 
monophosphate (cAMP)-mediated inhibition, and CD39- and/or CD73-generated, 
adenosine receptor 2A (A2AR)-mediated immunosuppression. Another mechanisms 
are targeting DCs and include the modulation of maturation and function of DCs 
through lymphocyte-activation gene 3 (LAG-3)–MHC-class-II-mediated suppression 
of DC maturation, and CTLA4–CD80/CD86-mediated induction of indoleamine 2,3-
dioxygenase (IDO) (29). 
 
1.1.2.4 Humoral immune response 
 
Antibodies in the blood and extracellular fluids provide humoral immunity of the 
adaptive immune system. They show diverse biological functions, they can bind 
extracellular pathogens or their products. They can be further neutralized, opsonized 
or the complement system can be activated. Activated B cells produce pathogen-
specific antibodies. They are required for their activation, proliferation and 
differentiation into antibody-secreting plasma cells. As a stimulus for production of 
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these pathogen specific antibodies serve a specific antigen contact and interaction 
with Th cells. (99) 
 
1.1.2.5 Costimulatory and co-inhibitory molecules 
 
Co-stimulatory and inhibitory molecules are important for the activation of T cells 
through DCs. Many of these molecules have been identified and this section focuses 
on the ones that have been well characterized. The TCR-inducible co-stimulatory 
receptor (ICOS), homologous to CD28 and cytotoxic T lymphocyte antigen-4 (CTLA- 
4), interacts with its ligand on APCs thereby enhancing effector T cell responses (65). 
ICOS becomes up-regulated within 6 to 48 hours after stimulation on T cells and 
delivers a co-stimulatory signal to T cells. This enhances T cell dependent antibody 
production and cytokine secretion by CD4+ T cells (49). The glucocorticoid induced 
tumor necrosis factor receptor (TNFR) family related gene (GITR) is a costimulatory 
molecule expressed on T cells (59). 
T cell immunoglobulin mucin 3 (TIM3) is usually expressed on Th1 and some CD8+ T 
cells and acts as a negative regulator on these cells, inducing apoptosis. TIM3 is up 
regulated during a late stage of T cell differentiation and is expressed on 
dysfunctional or exhausted CD8+ T cells (98, 136).  
Programmed cell death-1 (PD-1) is described to be a co-inhibitory receptor 
expressed on T cells and signaling through it attenuates TCR signaling and inhibits 
cytotoxic functions. Following TCR stimulation, PD-1 is expressed on T cells and 
binds members of the B7 family (PD-L1 (B7-H1) and PD-L2 (B7-DC)). Its ligand PD-
L1 is up-regulated on hematopoietic and non-hematopoietic cells and its signaling 
down-regulates TCR signaling, inhibiting proliferation and cytokine secretion which 
promotes anergy and apoptosis, leading to immune suppression (10, 105). CTLA-4 is 
an inhibitory molecule and a homolog of the co-stimulatory molecule CD28. It has 
higher affinity than CD28 to the B7 family ligands CD80 and CD86. CTLA-4 becomes 
transiently up-regulated on T cells shortly after activation and interaction with its 
ligands prevents continuous T cell co-stimulation and activation (147).  
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Figure 1.2 Coinhibitory pathways (121) 
Exhausted T cells can express multiple inhibitory receptors, which modify the outcome of a T 
cell antigen receptor signal and limit the population expansion, functional activity and survival 
of T cells.   
 
 
The lymphocyte-activation gene 3 (Lag3) is a CD4 homolog which binds MHC class II 
molecules with a higher affinity than CD4 (124). It is up-regulated on T cells after 
activation and negatively regulates T cell expansion and activation (40). 
 
1.1.2.6 Adenosine metabolism 
 
An interesting and newly described mechanism of T cell immunosuppression involves 
the two ecto-enzymes CD39 (ecto-nucleoside triphosphate diphosphohydrolase 1 or 
ATPase/ADPase) and CD73 (ecto-5’-nucleotidase), which removes the 
proinflammatory signal ATP from extracellular spaces and generates anti-
inflammatory adenosine (65). CD39 is the rate-limiting enzyme in the cascade. It 
converts immune activating extracellular ATP or ADP into AMP, which can then be 
used by CD73 to generate adenosine. Adenosine is an immune suppressive 
molecule and binds to the A2A receptor on effector T cells, which then become 
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suppressed because of elevated intracellular production of cyclic AMP (cAMP) (49, 
50).  
 
 
 
 
Figure 1.3 Metabolism of extracellular adenosine and its effect of cellular immunity 
(18) 
The activities of CD39 and CD73 lead to production of extracellular adenosine, which is 
decreased by adenosine deaminase (ADA)- dependent catabolism or by cellular uptake 
through nucleoside transporters (NT). Increased level of extracellular adenosine stimulates 
A2AR and A2BR on immune cells. Adenosine is suppressive to effector T cells, NK cells and 
NKT cells. These suppressive activities may by further enhanced by adenosine-mediated 
Treg, tolerogenic APCs or MDSC suppression.  
 
 
Adenosine has also been shown to modulate DC maturation and thereby favor a 
tolerogenic phenotype (137). Adenosine has a very short half-life, which makes close 
proximity necessary for effective suppression through this pathway. Interestingly, it 
has also been shown that the transfer of cAMP from Tregs through gap junctions into 
effector cells or DCs can directly inhibit these cells (17, 19). 
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1.1.2.7 Proliferation markers 
 
Different markers are described to indicate proliferation of T cell. The most commonly 
used marker is a Ki67. Ki67 is a nuclear protein present in the active stages of the 
cell cycle (G1, S, G2 and M phase), but absent in resting cells (G0 phase) (109). 
Therefore, it can be used to determine the proliferative potential of cell populations.  
Different techniques allow determining cell proliferation, such as the incorporation of 
BrdU, a thymidine analogue, into the chromosomal DNA. (72) 
 
 
1.2 Retroviruses 
Retroviruses are a large group of RNA viruses. Their virions are 80-100 nm diameter, 
their envelope consist of and display viral glycoproteins. Retroviruses are broadly 
divided into two groups: simple and complex. Retroviruses are composed of 3 
domains, which encode different virion proteins: gag, from which are derived internal 
viron proteins which form the matrix, the capsid, and the nucleoprotein structures, 
pol, which consist of information of reverse transcriptase and integrase enzymes and 
env, which directs the synthesis of surface and transmembrane envelope proteins. 
Additional, smaller domain, called pro, encodes virion protease. As simple viruses 
consist mainly of the above genes, complex viruses contain also of different genes 
encoding further regulatory and accessory proteins. (41) 
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Figure 1.4 Retroviral genome 
A. A genome of simple retrovirus consisting of four major domains: gag, pro, pol and 
env. 
B. A genome of complex retrovirus containing, additionally, information for other 
regulatory proteins.  
 Adapted after: © 1997 by Cold Spring Harbor Laboratory Press 
http://tolweb.org/treehouses/?treehouse_id=4426 
 
 
Retroviruses are divided in 3 different groups: oncoviruses, lentiviruses and the 
spumaviruses. Furthermore, oncoviruses are divided in 5 subgroup (α,β,γ,δ,ε – 
viruses). (41) 
 
1.2.1 Retroviral life cycle 
Retroviral replication starts by binding viral envelope proteins to entry receptor of a 
host cell. The replication of retroviruses takes place in several stages. 
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First, retroviral replication starts by binding the viruses with their glycoproteins in the 
lipid bilayer specific surface receptors of the host cell (1). After adsorption and fusion 
of the viral membrane with the host cell membrane, the capsid reaches the cytoplasm 
of the host cell (2). In the cytosol, the viral proteins as well as the RNA strands are 
released. Using reverse transcriptase, the viral RNA in double-stranded (ds) DNA is 
rewritten (3), which is further transported into the nucleus by viral and cellular 
proteins (4). In the nucleus, the viral DNA is integrated into the host cell genome by 
the Integrase (5). The DNA of the host cell of the provirus is transcribed by the RNA 
polymerases II and other transcription factors (6). Next, the mRNA of the provirus is 
transported back to the cytosol and there translated (7). Newly formed nucleocapsids 
attach to the plasma membrane and it comes at the cell surface using the proteins for 
packaging of viral particles. The budding at the cell membrane or the release of the 
viral particles is also called budding (8). 
 
 
 
Figure 1.5 Retroviral life cycle (133) 
a. Steps of viral entry: binding to a specific receptor on the cell surface; membrane fusion 
either at the plasma membrane or from endosomes (not shown); release of the viral core and 
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partial uncoating; reverse transcription; transit through the cytoplasm and nuclear entry; and 
intergration into cellular DNA to give a provirus 
b. Steps of viral exit: transcribtion by RNA polymerase II (RNAPII); splicing and nuclear 
export of viral RNA; translation of viral proteins, Gag assembly and RNA packaging; budding 
through the cell membrane; and release from the cell surface and virus maturation.  
 
1.2.2 Human Immunodeficiency Virus-1 
HIV-1 the causative agent of AIDS (acquired immunodeficiency syndrome) was 
discovered in 1983 (19, 105). It is a complex retrovirus (lentivirus) and possesses all 
components of a simple retrovirus with the addition of regulatory (Tat and Rev) and 
accessory (Nef, Vif, Vpr and Vpu) proteins. HIV-1 infects cells by binding of gp120 to 
CD4, present on CD4+ T cells, macrophages and DCs as well as by interaction with a 
co-receptor. There are two co-receptors which can potentiate infection, CXCR4 and 
CCR5. Different strains of HIV-1 can utilize these two co-receptors to varying 
degrees which is a major determinant of viral tropism. HIV-1 infection causes a long 
lasting disease characterized by a long incubation period, which is usually 
asymptomatic, and eventual progression to AIDS, if untreated (69). The routes of 
transmission are either horizontally; by sexual contacts or contact to contaminated 
blood (blood transfusion, intravenous drug use); or vertically (mother to child) (142). 
(140).  
The first antiretroviral drugs were developed in the nineties and given in single or 
dual combination. However, this could only control viral loads temporarily due to drug 
resistance by viral escape mutants. In the following years, the highly active 
antiretroviral therapy (HAART) a combination of three different antiretroviral drugs 
was developed. There are different antiretroviral drugs available targeting different 
stages of the retroviral life cycle: reverse transcriptase inhibitors (nucleoside or 
nonnucleoside), protease inhibitors, entry blockers and integrase inhibitors. This 
combination therapy has been shown to be more efficient in suppressing viral loads 
and reducing the levels of drug resistant HIV-1 strains in infected individuals. Some 
retroviral drugs have severe side effects, but due to the development of new drugs 
and better treatment regimes, these side effects have been greatly reduced. This 
makes HIV-1 infection a chronic but treatable disease in the western world where the 
access to HAART is available. However, due to the high costs of HAART and 
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insufficient education about HIV-1 infection routes, there is still a high incidence of 
HIV-1 infection and AIDS-induced death in developing countries, with millions of new 
infections every year. (70, 140) 
 
1.2.3 Friend virus as a model of retroviral infection 
Friend virus, discovered in 1957 by Charlotte Friend, belongs to γ-retroviruses. It is a 
retroviral complex of two viruses: Friend murine leukemia virus (F-MuLV), which is 
the apathogenic, replication competent helper virus and Spleen Focus Forming Virus 
(SFFV), which is the pathogenic, but replication defective helper virus. Due to various 
deletions in env gene the SFFV is not able to build viral particles. (41) Therefore F-
MuLV is required for replication and packaging SFFV genome into the viral particlesi. 
During the course of infection erythroid precursor cells are infected, as wells as other 
cell types, as lymphocytes, monocytes, dendritic cells etc. F-MuLV infection in adult 
mice is aphatogenic. If newborns are infected with F-MuLV they suffer anemia, 
splenomegaly and erythroleukemia due to immature adaptive immune response.  
In the beginning of FV infection SFFV viral envelope protein gp55 binds to 
erythropoietin receptor (EpoR) on the cell surface of erythroid precursor cells, giving 
a false signal for proliferation of them. During next 48 hours in susceptible mice 
uncontrolled proliferation occurs and infected erythroblasts migrate from bone 
marrow to the spleen, causing enlargement of the spleen. This is followed by 
integration of SFFV into site-specific target, spi-1 gene (SFFV proviral integration 
site-1). This leads to activation and overexpression of transcription factor PU.1 
erythroid cells and inhibition of their differentiation. Tumor suppressor gene p53 loss 
take place, what effect with uncontrolled proliferation of transformed cells.  
In adult susceptible mice FV complex induces severe splenomegaly and lethal 
erythroleukemia. In resistant strains FV infection leads to strong immune response in 
acute face of infection, however mice are not able to completely eliminate the virus, 
which persists lifelong. (41, 58) 
 
1.2.4 Immunoresponce against retroviral infection 
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Mice susceptible to FV develop during FV infection malignant erythroleukemia, 
however mice resistant to FV develop merely shortly splenomegaly. There are 
different genes responsible on FV-susceptibility. The resistance to FV infection is due 
to 6 genes Fv 1-6.  Fv 1,4 prevent from cell infection, Fv 2,5 regulate proliferation and 
differentiation of erythroblast, Fv 3 modify the immune response. Four MHC genes, 
which were described in H-2 mouse mediate resistance and may influence immune 
response (Rfv 1-3). For the presentation of viral T cell epitope H-2 genes are 
essential. The protection against FV-induced erythroleukemia consists of efficient 
interplay between FV-specific CD8+ T cells, Th cells and neutralizing antibodies. Due 
to haplotype H-2b, C57BL/6 mice are resistant to FV-induced erythroleukemia, they 
contain Fv 2 gen, which restricts proliferation of erythroblasts. [139]. On the contrary 
to C57BL/6 mice, BALB/c mice contain susceptible H-2d haplotype. Through the 
cross between both of this population, the new F1 generation, CB6F1 mice (Fv 2s/r, 
haplotype H-2b/d), can be created,. The CB6F1 mice are susceptible to FV-induced 
erythroleukemia [140, 141]. Heterozygotes own H-2 gens, therefore the FV-specific 
immune response occurs slower. The infection cannot be fully eliminated from the 
virus. [142]. 
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Aim and scope of work 
Subpopulations of myeloid cells are key players in the regulation of cellular immune 
responses. During retroviral infection, cytotoxic virus-specific CD8+ T Lymphocytes 
(CTLs) efficiently control acute virus infections but become exhausted when a chronic 
infection develops. A recently discovered population of myeloid derived suppressor 
cells (MDSCs) can restrain T cell responses by showing suppressive activity. The 
inhibition of T cells by MDSCs was first observed in tumor models. Although first 
information about the role of MDSCs in infectious diseases was generated, their 
function has to be studied in much more detail.  
The main aim of this project was to characterize the expansion of different MDSC 
subpopulations during acute Friend virus (FV) infection. As the mechanisms of T cell 
suppression by MDSC during retroviral infection are still elusive, phenotypic and 
functional properties of FV-induced MDSCs were assessed. Furthermore, it was of 
interest to establish a model for assessing functionality of these cells in vitro. In order 
to characterize mechanisms involved in MDSCs mediated T cell suppression several 
pathways were investigated with the help of cells from knockout animals or chemical 
inhibitors. To confirm the suppressive function of MDSCs in the living mouse and 
establish protocols for in vivo functionality of MDSC during acute FV infection, 
specific depletion experiments were performed.  
Different inhibitory mechanisms, such as T regulatory cells (Tregs) and inhibitory 
receptors play an important role in the regulation of immune responses during 
chronic infections. In order to show the contribution of MDSCs in T cell suppression 
the interplay between MDSC, Tregs and inhibitory receptors and their ligands was 
assessed. Simultaneous depletion of different inhibitory mechanisms allowed us to 
gain deep insight into mechanisms of immunoregulation and new approaches for 
restoration of T cell responses. 
Therefore, this study contributes to existing knowledge on the biology of MDSC, 
providing new insights into the role of these cells in chronic infections and possible 
new immune therapy of retroviral infections.  
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2. Materials  
2.1 Laboratory animals 
 
All animal experiments were performed in strict accordance with the German 
regulations of the Society for Laboratory Animal Science (GV-SOLAS) and the 
European Health Law of the Federation of Laboratory Animal Science 
Associations (FELASA). Protocols were approved by the North Rhine-Westphalia 
State Agency for 
Nature, Environment and Consumer Protection (LANUV). For all the experiments 
mice were older than six weeks. The mice were kept in a pathogen-free 
environment with free access to water and standard mouse food. All mice were 
under controlled and regular examination by veterinarians of the University 
Hospital Essen. 
The mice used in this PhD thesis had the resistance genotype of H-2Db/b, Fv-1b/b, 
Fv- 2r/r, Rfv3r/r and were bred on C57BL/6 (B6) background. The exceptions are 
BALB/c mice, which are susceptible to FV-induced leukaemia and splenomegaly 
and were used to produce virus stocks in vivo, and Y10A (F1: A.BY x C57BL/10A) 
mice, which are also susceptible to FV and were used to titrate the virus stocks. 
 
2.1.1 Wild type mice 
 
BALB/c Harlan Winkelmann GmbH, 
Borchen, Germany, 
Resistance genotype: H-
2Dd/d, FV-2s/s 
 
C57BL/6 (B6) Harlan Winkelmann GmbH, Resistance genotype: H-
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Borchen, Germany 
 
2Db/b, FV-2r/r 
 
F1: A.BY x 
C57BL/10A 
Bred at the Animal Facility, 
University Hospital Essen, 
(Y10A) Germany 
 
Resistance genotype: H-
2Da/b, FV-2r/s 
 
 
2.1.2 Knock out mice 
 
TCRtg CD8 TCR 
transgenic mice  
The DbGagL TCR Tg (T cell receptor transgenic) mice 
were specific for the DbGagL FV epitope (30). Mice were 
maintained at animal facilities, University Hospital Essen, 
Germany. 
DEREG DEREG (depletion of regulatory T cell) mice were 
generated from bacterial artificial chromosome (BAC) 
technology. These mice express a diptheria toxin receptor 
(DTR) enhanced green fluorescent protein (eGFP) fusion 
protein under the control of the foxp3 locus. DEREG mice 
allows both detection and inducible depletion of Foxp3+ 
Treg cells.  
Kindly provided by Dr. Tim Sparwasser (Institut für 
Medizinische Mikrobiologie, Immunologie und Hygiene, 
Technische Universität München, Munich, Germany) and 
maintained at animal facilities of University Hospital Essen.  
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PD-L1 KO In this mice exon 1 and a large part of exon 2 in the 
endogenous B7-H1 allele is replaced with a Neo-resistance 
cassette by a gene-targeting vector, which leads to 
deleting the sequences encoding the signal peptide and 
the majority of the extracellular IgV domain of PD-L1. (32) 
Mice were originally generated by Lieping Chen ( 
Department of Immunology, Mayo Clinic College of 
Medicine, Rochester, USA) and maintained at animal 
facilities of University Hospital Essen, Germany 
CD39 KO Mice with a targeted disruption of exon 1 in the 
ectonucleotide triphosphate diphosphohydrolase (entpd1) 
gene, which leads to a shorter transcript of the gene and 
no detectable function of the enzymatic protein product 
CD39. Mice were kindly provided by Verena Jendrossek 
(Institute for Cell Biology, University Hospital 
Essen,Germany). Mice were generated by Simon C. 
Robson (Department of Medicine, Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, MA, 
USA) (50) and inbred at the animal facilities, University 
Hospital Essen, Germany. 
 
 
2.2 Cell lines and viruses 
2.2.1 Cell lines 
Mus dunni cell line is susceptible to infection with FV was used to determine the 
productivity of virus infected cells in vitro. Mus dunni cells were maintained in 
complete RPMI medium supplemented with 10% FCS and 0.5% 
Penicillin/Streptomycin. 
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2.2.2 Friend virus 
The FV stock used for the experiments was a FV complex containing B-tropic 
Friend Murine Leukemia Helper Virus (F-MuLV) and polycythemia-inducing spleen 
focus-forming virus (SFFV) (19).Two different virus stocks were used:  the virus 
containing only FV complex (31), for acute infections, and the virus containing 
additionally lactate dehydrogenase-elevating virus (LDV), for experiments with 
combinatorial treatment. The addition of LDV enables a more stable chronic 
infection with the FV to be established (127). 
 
2.3 Chemicals and media 
 
Chemicals, buffers and media were purchased from Applichem, Invitrogen, Merck, 
Roth and Sigma-Aldrich unless otherwise stated.  
 
3-amino-9-ethylcarbazole (AEC), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 
adenosine 5’- (α,β-methylene)diphosphate (AMPCP), acetic acid, autoMACS run 
and wash buffer (Miltenyi Biotec), β-mercaptoethanol (β-ME), bovine serum 
albumin (BSA), brefeldin A (BFA), calcium chloride, dextran, dimethyl sulfoxid 
(DMSO), disodium hydrogen phosphate, Dulbecco´s modified Eagle medium 
(DMEM) (Gibco) and DMEM high glucose (Gibco), ethanol, 
ethylendiaminetetraacetic acid (EDTA), FACS Clean (BD Bioscience), FACS Flow 
(BD Bioscience), FACS Rinse (BD Bioscience), fetal calve serum (FCS) 
(Biochrom), Ficoll (GE Healthcare), 37 % formaldehyde, formalin, FuGENE® 
transfection reagent (Promega), glucose, hydrogen peroxide (H2O2), incidine 8%, 
isopropanol, L-Glutamine, magnesium chloride (MgCl2), N-Ndimethylformamid, 
penicillin-streptomycin (PenStrep), phosphate buffered saline (PBS) (Gibco), picric 
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acid, polybrene A, potassium ferricyanide, potassium ferrocyanide, RPMI-1640-
Media (Gibco), saponin, sodium carbonate, sodium acetate, sodium azide (NaN3), 
sodium pyruvate, trypan blue, trypsin-EDTA. 
 
2.3.1 Antibiotic 
Penicillin / Streptomycin (Gibco) 
 
2.3.2 Buffer and supplemented cell culture media 
 
If not stated otherwise all buffer and media were prepared using bi-distilled H2O. 
 
Table 2.1 Buffer and supplemented cell culture media 
Media Composition 
Culture medium 
 
500 ml RPMI 1640 (Gibco) 
10% FCS (Gibco) 
0.5% Penicillin/Streptomycin mixture 
FACS buffer 
1l Phosphate buffered saline (PBS) 
0.02% Na-azide 
0.5% BSA 
Freezing mediums 
 
40% FCS 
10% DMSO 
50% RPMI medium 
MACS buffer 
 
1 l (PBS)  
0.5 % BSA  
2 mM EDTA 
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PBBS 
 
1 l (PBS) 
1.0 g glucose 
 
 
2.4 Antibodies and staining reagents 
 
2.4.1 Characteristics of fluorophores  
Antibody-coupled fluorochromes and their absorption- and emission maxima are 
described in a table. 
Table 2.2 Characteristics of fluorophores 
Fluorochrom  Absorption Emission 
Fluorescein-
isothiocyanat 
FITC 488 525 
R-Phyccoerythrin PE 488 575 
Peridinin-
Chlorophyll-
Protein Komplex 
PerCP 488 670 
Phycoerythrin-Cy7 PE-Cy7 488 785 
Allophycocyanin APC 633 660 
Allophysocyanin-
Cy7 
APC Cy7 635 785 
Alexa Fluor 700 AF 700 635 723 
Materials 
 
 
30 
 
eFluor 450 eF 450 405 455 
eFluor 605 eF 605 590 605 
eFluor 650 eF 650 635 650 
 
 
2.4.2 Antibodies 
Anti-mouse antibodies were purchased from eBioscience (Affymetrix), BD 
Bioscience or BioLegend unless otherwise stated. 
Table 2.3 Antibodies 
  Fluorochrom Clone Manufacturer 
AB720 (α-MuLV 
Env, Isotype 
IgG2b) 
    
AB720 (α-MuLV 
Env, Isotype 
IgG2b)* 
 AF647   
Arg1 
anti-
human/mouse 
 FITC   R&D Systems 
CD3 anti-mouse  Alexa Fluor 700 17A2 eBioscience 
CD11b anti-
mouse 
 BV 650 M1/70 BioLegend 
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CD11b 
Rat anti-mouse 
 PE CF594 M1/70 BD Horizon 
CD11c anti-
mouse 
 BV510 N418 BioLegend 
CD16/32 Fc-Block - Clone 93 eBioscience 
CD19 anti-mouse  eFluor 605 NC eBio1D3 eBioscience 
CD19 anti-mouse  PE eBio1D3 eBioscience 
CD39 anti-mouse  PerCP eFluor 
780 
24DMS1 eBioscience 
CD43 anti-mouse  PerCP 1B11 BioLegend 
CD49b anti-
mouse 
 PE Dx5 eBioscience 
CD73 anti-mouse  PE Cy7 TY/11.8 eBioscience 
CD80 anti-mouse  APC 16-10A1 eBioscience 
CD274 anti-
mouse 
(PD-L1) 
 
PE MIH5 eBioscience 
FVD  APC-Cy7  eBioscience 
Gr1 
(Ly6G/Ly6CLy6G) 
anti-mouse 
 eFluor 450 RB6-8C5 eBioscience 
Gr1 
(Ly6G/Ly6CLy6G) 
 FITC RB6-8C5 BioLegend 
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anti-mouse 
Gr1 
(Ly6G/Ly6CLy6G) 
anti-mouse 
 APC RB6-8C5 BioLegend 
GzmB anti-
human/mouse 
 APC GB12 invitrogen 
IL-2 anti-mouse     
IFNγ 
anti-mouse 
 APC XMG1.2 eBioscience 
KI67 
anti-mouse/rat 
 PE Cy7 SolA15 eBioscience 
Ly6C 
anti mouse 
 PerCP Cy5.5 HK1.4 eBioscience 
Ly6G  AF700 1A8 BioLegend 
NK1.1 
anti-mouse 
 BV421 PK136 BioLegend 
NK1.1 
anti-mouse 
 eFluor 605 PK136 BioLegend 
NOS2 
anti-mouse 
 PE-eFluor 610 CXNFT eBioscience 
Streptavidin  eF610 - eBioscience 
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TER119  PE-Cy7 TER-119 eBioscience 
TNFα 
anti-mouse 
 PE-Cy7 MP6-XT22 BioLegend 
 
2.5 MHC tetramers and F-MuLV specific peptide 
 
2.5.1 MHC I tetramer 
PE labelled MHC class-I H-2Db tetramer loaded with the peptide 
AbuAbuLAbuLTVFL (DbGagL tetramer, FV gag CD8+ epitope gPr80gag85-93) 
recognised by DbGagLspecific CD8+ T cells (2, 124, 134). The MHC class-I 
tetramer was purchased from Beckman and Coulter (Krefeld, Germany) or MBL 
International Corporation (Woburn, MA, USA). 
 
2.5.2 CD8 peptide 
The F-MuLV CD8+ T cell peptide was synthesised by PAN Tecs (Tübingen, 
Germany) and reconstituted in 100 % sterile DMSO. Peptide name: FMR-H-2Db 
GagL CD8 epitope. Sequence: AbuAbuLAbuLTVFL (30). 
 
2.6 Discrimination of dead cells 
To discriminate dead from live cells, either propidium iodide (PI) or fixable viability 
dye (FVD) eF780 were used. 
 
2.7 Staining reagents 
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Table 2.4 Staining reagents 
Staining reagent Manufacturer  
 
FVD eF780 eBioscience 
CFSE Invitrogen 
Violet tracer Invitrogen 
 
2.8 Standard kits 
Table 2.5 Standard kits 
Kit  Manufacturer 
Cytofix/ Cytoperm Intracellular staining 
kit 
BD Pharmingen, Heidelberg 
Foxp3 staining set  eBioscience, San Diego, USA 
Cytofix/cytoperm intracellular staining kit  BD Pharmingen, Heidelberg, Germany 
Mouse CD8α (Ly-2) isolation kit 
 
Miltenyi Biotec, Bergisch Gladbach, Germany 
 
Myeloid-Derived Suppressor Cell 
Isolation Kit (mouse) 
Miltenyi Biotec, Bergisch Gladbach, Germany 
 
 
2.9 Depletion antibody and treatment reagents 
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Table 2.6 Depletion antibody and treatment reagents 
InVivoMAb anti m Ly6G 
 
Ly6G antibody, Clone 18A,  
purchased from BioXcell  
 
InVivoMAb anti m Tim3 
 
Tim3 antibody, Clone RMT3-23 
purchased from BioXcell  
 
InVivoMAb anti m PD-L1 
 
PD-L1 antibody, Clone 10F.9G2 
purchased from BioXcell  
 
5-Fluorouracyl (5FU) 
 
2,4-Dihydroxy-5-fluoropyrimidine, 
purchased from Sigma-Aldrich 
Diphteria toxin (DT) Diphtheria toxin, Corynebacterium 
diphtheria – Calbiochem, purchased 
from Merck.  
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3. Methods 
3.1 Animal trials 
The animal experiments were conducted according to the guidelines of the 
Federation of European Laboratory Animal Science Association. 
 
3.2 Infection  
The infection of mice with Friend Virus was conducted by intravenously (i.v) 
injection in the lateral tale vein using 25G-hollow needle. Virus stock used for 
infection was thawed, centrifuged and the supernatant diluted in sterile PBS. For 
acute FV infection of mice 20 000 SFFU (Spleen Focus Forming Units) were used. 
For experiment with combinatory treatment with DT, αPD-L1 and αTim3, FV + LDV 
was used in concentration 20 000 SFFU of FV. 
 
3.3 Intraperitoneal injection (i.p.) 
The in vivo depletion antibodies as well as 5FU and Diphtheria toxin were 
administered via intraperitoneal (i.p) injection. Mice were hold by the skin at the 
back of the neck and the tail was held back. Mice were hold with the ventral side 
exposed and tense, therefore internal organs are not harmed by the injection. The 
injection was done in a 45° angle into the lower abdomen and slowly administered.  
 
3.4 Dissection of mice 
Mice were sacrificed using cervical dislocation after anesthesia with isofloran. 
Then, the mice were then fixed with needles and carefully cut open in order not to 
destroy internal organs. First the cervical, axillary and inguinal lymph node were 
removed. Next the peritoneal cavity was opened. The spleen was removed by 
excising both blood vessels. To dissect the bone marrow, hind legs were cut loose 
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and the flesh was removed. All organs and tissues were kept in PBBS on ice until 
further preparation. 
 
3.5 Preparation of single cell suspension 
Spleen and lymph nodes were homogenized through a 70 μm cell strainer with 
help plunger of a syringe. The strainer was washed from the strainer using PBBS. 
An aliquot of cell suspensions was removed to count the cells. Cells were then 
centrifuged at 300 xg for 10 min and the supernatant was discarded. Based on the 
cell count, cells were re-suspended in an appropriate volume of PBBS. 
A bone marrow cell suspension was delivered by flushing the femur and tibia of 
hind leg with a 23G-hollow needle with PBBS. An aliquot of cell suspension for 
counting the cells was removed. The cells were subsequently centrifuged at 520 
xg for 10 min and the supernatant discarded. Based on the cell number the cells 
were re-suspended in an appropriate volume of PBBS. 
 
3.6 Preparation of bone marrow derived dendritic cells 
To generate mouse DCs, the bone marrow from a naïve B6 mouse was prepared 
as described above and re-suspended in 50 mL mouse DC media supplemented 
with 1 ng/mL mrIL4 and 5 ng/mL mrGM-CSF. 10 mL were then seeded into a 10 
cm cell culture dish and incubated at 37 °C and 5 % CO2 for seven days. After 24 
hours an additional 10 mL of supplemented mouse DC media was added to the 
culture. Five days after seeding, the cells were washed once by centrifuging the 
cell culture media at 400 xg for 6 min (these cells are non-adherent). The cells 
were then re-suspended in 20 mL supplemented mouse DC media and cultured 
for another two days. Seven days after initially seeding the bone marrow cells, the 
differentiated DCs could be used for other applications. 
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3.7 Peptide stimulation of mouse CD8+ T cells with peptide-loaded mouse 
DCs  
Bead-isolated CD8+ T cells from naïve TCRtg mice (55) were incubated for 
different lengths of time with F-MuLV CD8+ T cell peptide loaded onto mouse DCs 
in complete RPMI. DCs were loaded with 5 μg peptide (AbuAbuLAbuLTVFL) for 1 
hour at 37 °C. After loading, the DCs were washed, counted and seeded at a ratio 
of 1 DC to 5 CD8+ T cells.  
 
3.8 In vivo production of a FV stock 
To obtain a FV stock, susceptible BALB/c mice were infected intra venously (i.v.) 
with 3000 spleen focus forming units (SFFU) of FV. Nine days post infection the 
mice were sacrificed and the spleens removed. A 15 % spleen homogenate was 
prepared in PBBS with 1 mM EDTA. The homogenate was then aliquoted and 
stored at -80°C until use. 
 
3.9 Titer determination of a FV stock 
Titration of a FV stock was done by infecting Y10A mice i.v. with different amounts 
of virus stock. The spleens were removed 14 days post infection. During the 
course of FV infection, malignant cell populations develop on the surface of the 
spleen. These foci can be visualized by incubation of the whole spleens in Boulin´s 
solution which enhances the visual contrast of foci on the spleen surface. SFFUs 
can be determined by counting these foci. 
 
3.10 In vivo depletion of cell populations 
To deplete MDSCs two depletion methods were used. First, 5-Fluorouracil was 
diluted to concentration 10mg/kg per mouse in 500µl PBS and injected i.p. once, 
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four days prior sacrifice. With this method depletion of all MDSCs was performed 
(Figure 4.6).  
To deplete only gMDSCs αLy6G (Clone 1A8) was in vivo antibody was diluted 
100µg per mouse in PBS and administrated i.p. four times every third day (Figure 
4.6). 
T regulatory cells were depleted using a diphtheria toxin, mice were injected with 
DT diluted in PBS i.p. three times every third day (Figure 4.6). 
For immune checkpoint blockade in vivo antibody for αPD-L1 (10F.9G2) and Tim3 
(RMT3-23) were used. Mice were injected with 250µg αPD-L1 three times every 
third day, and with 100µg Tim3 three times every second day.  μg per i.p. injection 
was used (Figure 5.5).  
The depletion efficiency was assessed via cell specific markers using flow 
cytometry. 
 
3.11 In vivo cytotoxicity assay 
In vivo cytotoxicity assay allows determining cytotoxic function of T cells after 
MDSCs depletion during FV infection. (182) Lymphocytes were isolated from 
lymph nodes and spleens from naive mice (donor mice). Single cell suspensions 
were prepared and the cells were washed with 40 ml of PBS. Mononuclear cells 
from the spleens were separated additionally by erythrocytes lysis. Consequently, 
cells were washed twice in 50 ml of PBS. Cell suspensions from lymph nodes and 
erythrocyte lysed spleen cells were mixed and divided into equal volumes of 15 ml 
of RPMI medium into two tubes. The cells from one tube were loaded with the 
class I-restricted peptide recognized by CD8+ T cells for 1,5 h at 37°C and 
afterwards were stained with 40nM CFSE (carboxyfluorescein succinimidyl ester) 
dye for 10 min at 37°C and then for 5 min on ice (target cells, experimental). The 
second tube was incubated for 1,5 h at 37°C and stained with 7,5µM Violet Tracer  
The phenotype of these cells would be CFSE- high . The unloaded cells remained 
intact and would be separated from the target cells as CFSE-low (control cells). 
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Peptide loaded and unloaded cells were counted using Trypan blue exclusion 
microscopy and suspended in sterile PBS in the ratio 1:1. 1.0×107 cells of each 
population (per mouse) were injected intravenously (i.v.) into FV infected and 5FU 
treated mice. One hour after i.v. injection of the donor cells, recipient mice were 
sacrificed. Subsequently, in vivo killing activity was quantified in single-cell 
suspensions from the spleen, lymph nodes and bone morrow of each FV infected 
mouse. The percentage of killing was calculated as follows: 100 − {[(% of peptide 
loaded in infected cells / % of peptide unloaded in infected cells) / (% peptide 
loaded in uninfected cells / % peptide loaded in uninfected cells)] × 100}. 
 
3.12 Infectious center assay (IC assay) 
To detect the number of infectious centers of FV-infected cells, 2x104 Mus dunni 
cells in 3 ml complete RPMI were seeded into each well of a 6-well plate. The cells 
were then incubated over night at 37 °C with 5 % CO2. The following day mouse 
cell suspensions (derived from spleen of FV-infected mice) were prepared, a 10-
fold dilution series formed (starting with 1x107 cells) and 1 ml of each dilution was 
added to a single well of the 6-well plate. The plate was then incubated for three 
days under the same conditions. During this incubation period, infected cells 
spread the infection to the Mus dunni cells via cell-cell contacts. Cell division of the 
Mus dunni transfers the provirus to their daughter cells what form an infected cell 
colony. To visualize the infected cell clones, the media on the Mus dunni cells was 
discarded and the cells were fixed by incubating them with 95 % ethanol for 10 
min. The ethanol was discarded and the plates washed twice with PBS plus 0.1 % 
BSA. The cells were then incubated for 2 hours at room temperature with 600 μl of 
culture supernatant of an AB720 producing hybridoma cell line. This hybridoma 
cell line produces an antibody (AB720) which specifically binds to the env-protein 
of F-MuLV recognizing FV-infected cells. After two hours the plates were washed 
twice with PBS plus 0.1 % BSA. 600 μl of a 1:400 dilution (into PBS) of secondary 
antibody conjugated to HRP (goat-α-mouse- IgG2b-HRP (0.05 mol/l)) was added 
to the cells for 90 min. After the incubation, the antibody was discarded and the 
plates were washed twice with PBS. The cells were then incubated for 20 min in 
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the dark with 2 ml of fresh AEC substrate solution. A red precipitate is formed by 
conversion of the soluble substrate AEC in the substrate solution into an in-soluble 
precipitate catalyzed by the HRP coupled to the secondary antibody. The 
substrate solution was discarded and the plates were washed twice with H2O. 
After the plates had dried over night the red spots in each well were counted and 
calculated for 1x106 added cells. To determine the IC count per 1x106 spleen cells 
the mean off all dilutions was formed. As a control an additional plate of Mus dunni 
cells was prepared a day before the experiment. Three wells of this plate were left 
uninfected and the other three wells were infected with free F-MuLV (with 8 μg/ml 
polybrene A to facilitate virus uptake). The appearance of red dots after 
developing the assay indicated functionality.  
 
3.13 Stimulation of freshly isolated mouse cells for cytokine production 
For the intracellular staining of cytokines (like TNFα, IFNγ and IL-2), freshly 
isolated mouse cells were stimulated in vitro. The wells of a Nunc MaxiSorp 96-
well plate were coated with 50 μL purified αCD3 antibody (10 μg/ml) in sodium 
carbonate coating buffer. The coating of the plate was done for overnight at 4°C. 
After αCD3 coating, the plate was washed three times with PBS. For stimulation of 
freshly isolated mouse cells, 1x107 cells were added to each well in duplicates. 
The cells were re-suspended in complete RPMI medium supplemented with 50 μM 
β-ME, 2 μg/ml purified αCD28 and 2 μg/ml BFA and incubated for 5 hours at 37°C. 
After stimulation, the cells were transferred into new wells and stained for surface 
molecules and intracellular cytokines. For controls, a sample was left unstimulated 
but stained with intracellular antibodies and a stimulated sample did not get 
stained with the intracellular antibodies. (183) 
 
3.14 Flow cytometry 
3.14.1 Principle of flow cytometry 
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Flow cytometry is a method used for the characterization and quantification of 
heterogeneous cell populations in solution. Using fluorescence labelled antibodies 
or fluorescently tagged proteins it allows to detect surface and intracellular 
molecules. Labelled and prepared cells are then measured on a fluorescence-
activated cell sorting (FACS) machine. The main components of a FACS analyzer 
can be divided in the fluidic system, the optical system and the detection system.  
In a cell solution the cells are randomly distributed in a three dimensional space. 
To detect the fluorescence signal of labelled molecules they need to be focused in 
a stream of single cells. The fluidic system is responsible for this process, whereby 
the cell suspension is taken up by the sample injection port and then usually 
hydrodynamically focused. (184-188) 
After focusing, the cells pass through the optical system and can be analyzed. 
FACS machines are equipped with different lasers, mirrors and filters. Two initial 
parameters are acquired by all FACS analyzers: forward scatter (FSC) and side 
scatter (SSC). To measure the size of cells, light that is scattered in a forward 
direction (FSC) is used. The granularity of cells is measured by the SSC channel, 
which is the light measured at a 90° angle. Combining the information of the FSC 
and the SSC is used for a pre-selection of cell types in a heterogeneous sample 
(Figure). 
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Figure 3.1  Principle of Flow Cytometry  
Two lasers (635 and 488 nm) send light trough the sample. The light emitted by the 
sample is then isolated by different filters and sent to the different PMT detectors. The 
PMT detectors transform and enhance the optical signal into an electric signal, which can 
then be visualized in the analysis software on a computer. 
 
 
If an antibody labelled cell passes through a light beam emitted by a single laser, 
the different fluorophores sensitive to that specific wavelength of light are 
specifically excited. When the electrons in the fluorophores become excited by the 
laser light they are lifted to a higher energy level and shortly after this they fall 
back to the original energy state emitting energy in the form of photons. The 
wavelength of these released photons is longer than that of the excitation light 
source, which is part of the phenomenon known as Stoke´s shift. The emitted light 
is reflected, filtered and detected with specific sets of optical mirrors, filters and 
detectors. The mirrors reflect the light onto filters, which filter light of specific 
wavelength. Short pass or long pass filters only allow light under or above a 
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certain wavelength (respectively) to pass and band pass filters are used to filter a 
certain range of wavelengths (Figure 3.1). The emitted and filtered light is then 
detected by the detectors (usually photomultiplier tubes (PMTs)). These detectors 
measure the amount of photons and their output signal is proportional to the 
amount of antibody bound to the cell. This type of measurement allows to collect 
the necessary information about quantify and characterization of the cells within a 
sample. The optical signal is then amplified and converted into an electric signal. 
This can be visualized in the analysis software (Figure 3.1). Multicolor flow 
cytometry is made possible by using different fluorophores which emit at 
wavelengths that can be discerned from each another. In this thesis an LSR II with 
four lasers (488 nm, 633 nm, 355 nm and 405 nm) and the software FACS DiVa 
BD bioscience) and FlowJo7.6.5 (Treestar) were used for acquiring and analyzing, 
respectively. It is also possible to sort cells, for this method cells pass through the 
above described system and are immediately characterized by previously 
established parameters. For sorting, the fluidic stream is broken into droplets, 
containing a cell each. These droplets then become charged by passing through 
an electric field and may be diverted into collection tubes by plates of opposite 
polarity. 
  
 
3.14.3 Surface staining of mouse cells for flow cytometry 
For flow cytometry cell staining of mouse cells usually 3-7x106 cells per sample of 
freshly isolated mouse cells were transferred into a well of a 96-well U-bottom 
plate and washed with the addition of 100 μl FACS buffer at 300 xg for 3 min at 4 
°C. The supernatant was discarded by flicking the plate. In case of staining of 
myeloid cells FC block was added to prevent unspecific binding of antibodies. 
Prior surface staining cells were re-suspended in 50μl FC block diluted in FACS 
buffer and incubated in the dark for 15 min at room temperature. After incubation 
time an antibody mix was prepared in 50μl FACS buffer and added to the cells. 
The cells were re-suspended in the antibody mix and incubated for 15 min at room 
temperature or 20 min at 4 °C. After incubation, the cells were washed by addition 
of 100 μl FACS buffer per well and spun at 300 xg for 3 min. The cells were then 
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either re-suspended in FACS buffer for further processing or directly transferred 
into FACS tubes for measurement on the LSRII or fixed as described below.  
3.14.4 Fixation of mouse cells 
Depending on the performed intracellular stain, the cells were either fixed with 
Cytofix/Cytoperm from BD or with the Foxp3 staining set from eBioscience. If only 
cytoplasmic molecules were to be stained, the Cytofix/Cytoperm kit was used. For 
this the cells were re-suspended in 100 μl fixing buffer and incubated for 10 min at 
room temperature. Next the cells were washed with 100 μl of Cytofix/Cytoperm 
wash buffer, centrifuged at 540 xg for 4 min and stained for intracellular molecules. 
If nuclear molecules were to be stained, the Foxp3 staining set was used. The 
cells were re-suspended in 100 μL Foxp3 Fix/Perm fixing solution which was 
prepared according to the manufacturer’s instructions (1:4 of Foxp3 Fix/Perm 
concentrate into diluent). The cells were left to fix for 2 to 4 hours at 4 °C. To stop 
the reaction 100 μl Foxp3 Fix/Perm wash buffer was added to each well and the 
cells were centrifuged at 540 xg for 4 min at 4°C and stained for intracellular 
molecules. The cells were then subsequently washed with the addition of FACS 
buffer and centrifuged at 540 xg for 4 min. Subsequently the cells were re-
suspended in FACS buffer for this application and measured immediately on the 
LSRII. 
 
3.14.5 Intracellular stain of mouse cells 
For intracellular staining, an antibody mix was prepared in 50 μl of either 
Cytofix/Cytoperm wash buffer or Fix/Perm wash buffer (Foxp3 staining set). The 
cells were re-suspended in the antibody mix and stained for 30 min at 4 °C and, 
after addition of 100 μl of the appropriate buffer, centrifuged at 540 xg for 4 min. 
The cells were re-suspended in FACS buffer and transferred into FACS tubes for 
measurement on the LSRII.  
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3.14.6 Tetramer class I stain 
A method to detect small populations of virus-specific CD8+ T cells is by the use of 
specific tetramers. T cell receptors (TCRs) recognize and bind to complexes which 
are expressed on APCs composed by MHC molecules and peptides with specific 
sequences processed by APC (MHC/peptide complexes). Monomeric 
MHC/peptide complexes were shown low affinity to the TCR and instability. To 
overthrow these difficulties MHC/peptide monomers are biotinylated and 
tetramerized with streptavidin to maintain stable binding to multiple TCR, enabling 
MHC/peptide tetramers to be used as a detection tool. MHC class I tetramers 
consist of four peptide- MHC class I complexes, which are linked by biotin-
streptavidin. The complex may be detected via conjugated fluorophores in a flow 
cytometer. The peptide used to build the tetramer complex is only bound by the 
TCR of specific CD8+ T cells in combination with the MHC class I (2, 36). A 
schematic of the MHC class I are shown in Figure 3.2. The tetramer class I stain 
was done as described for the extracellular flow stain with a dilution of 1:200. The 
tetramer class I stain was also proof to fixation with Cytofix/Cytoperm. 
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Figure 3.2 Schematic organization of MHC class I tetramer. 
MHC class I tetramers consist of four MHC class I molecules, linked via biotin (B) 
to a streptavidin (SA) on the fluorophore (in this case PE). The MHC complexes 
are loaded with a specific peptide. (36) 
 
3.14.7 Gating strategy for murine MDSCs 
To gate murine MDSCs a special strategy was utilized. MDSCs share different 
markers with different cell populations, therefore careful gating is necessary. To 
guarantee that only MDSCs were considered the following gating strategies for 
flow cytometric analysis ware used. 
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Figure 3.3 Gating strategy for murine MDSCs. To gate murine MDSCs firstly (A) 
lymphocytes, (B) singlets. Further dead and lineage (CD19, CD3, NK1.1) cells  
were excluded (C). CD11b+ cells were identified (D). MDSCs were characterized 
with help of Ly6C and Ly6G (E). In experiments with combinational therapy 
MDSCs were characterized as Gr1high and Gr1low cells and co-expression of 
CD11b+. 
 
3.14.8 Exclusion of dead cells in flow cytometry  
The exclusion of dead cells and cellular debris in flow cytometry was performed 
using the dye propidium iodide (PI) or fixable viability dye (FVD). In healthy cells, 
the cell membrane prevents access of PI to DNA. However, in damaged, apoptotic 
or dead cells, the membrane is not intact and unable to play its preventing 
function, allowing rapid PI access into the cell nucleus and DNA with which it 
interacts. This dye is useful for the DNA analysis and the dead cell exclusion 
during flow cytometric analysis. 0,5 μl of PI was added to the stained cells in 300 
μl FACS buffer to the sample and immediately analyzed.  
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Discrimination of dead cells in intracellular staining was performed with help of 
Fixable Viability Dye (FVD). FVD is a viability dye that can be used to label dead 
cells prior to fixation and/or permeabilization procedures. FVD stain is based on 
the reaction of a fluorescent reactive dye with cellular proteins (amines). These 
dyes cannot penetrate live cell membranes, so only cell surface proteins are 
available to react with the dye, resulting in dim staining. The reactive dye can 
infuse the damaged membranes of dead cells and stain both the interior and 
exterior amines, resulting more intense staining. FVD eF780 was added in amount 
of 1 μl per 1 mL of cells together with the surface staining antibodies.  
 
3.15 Cell isolation with the MACS technology 
For the isolation of mouse CD8+ T cells mouse CD8α (Ly-2) MicroBeads were 
used. (190) Using these beads CD8+ T cells are directly labelled. In general, the 
cells were counted and re-suspended in MACS buffer (90 μL buffer per 1x107 
cells) and the CD8α MicroBeads were added (10 μl beads per 1x107 cells). The 
mix was incubated for 20 min at 4 °C in the dark and subsequently re-suspended 
in 10-20 times the labelling volume of MACS buffer and centrifuged for 10 min at 
300 xg. Finally, the supernatant was carefully discarded and the cells were re-
suspended in up to 500 μL MACS buffer per 1x107 cells. To protect from clogging 
the cells were passed through a 30 μm cell strainer before applying to the MACS 
columns. The cells were then applied on the column connected to magnetic field. 
After washing the column remained cells were flushed with 5 ml MACS buffer. 
After enrichment the cells were centrifuged, counted and processed for the further 
application.  
 
For the isolation of mouse MDSCs mouse Myeloid Derived Suppressor Cells 
Isolation Kit was used (191) with a pre-isolation of CD19 cells (192). For pre-
isolation of mouse CD19- T cells mouse CD19 MicroBeads were used. Using 
these beads CD19+ T cells are directly labelled. In general, the cells were counted 
and re-suspended in MACS buffer (90 μL buffer per 1x107 cells) and the CD19α 
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MicroBeads were added (10 μl beads per 1x107 cells). The mix was incubated for 
15 min at 4 °C in the dark and subsequently re-suspended in 10-20 times the 
labelling volume of MACS buffer and centrifuged for 10 min at 300 xg. Finally, the 
supernatant was carefully discarded and the cells were re-suspended in up to 500 
μL MACS buffer per 1x108 cells. To protect from clogging the cells were passed 
through a 30 μm cell strainer before applying to the MACS columns. The cells 
were then applied on the column connected to magnetic field. After washing the 
column, passed through cells were collected, centrifuged, counted and processed 
for the further MDSCs isolation.  
In general, the cells then re-suspended in MACS buffer (350 µl buffer per 1 x 108) 
and the FC Block was added (50µl per 1x108). The mix was incubated for 10 
minutes at 4°C. After incubation, 100µl of biotin-conjugated αLy6G antibody was 
added, and the cells incubated for a further 10 min at 4°C. Cells were washed by 
adding 10 ml of buffer and centrifuged at 300 xg for 10 min at 4°C. The cells were 
re-suspended in 800µl of buffer per 1 x 108 and 200µl of anti-biotin MicroBeads 
was added, mixed well, and incubated for 15 min at 4°C. Cells were washed by 
adding 10ml of buffer and centrifuged at 300 xg at 4°C. The cell pellet was re-
suspended in 500µl of buffer, and magnetic separation was performed to positively 
isolate Gr1high Ly6G+. To protect from clogging the cells were passed through a 30 
μm cell strainer before applying to the MACS columns. The cells were then applied 
on the column connected to magnetic field. After washing the column remained 
cells were flushed with 5 ml MACS buffer. After enrichment the cells were 
centrifuged, counted and processed for the further application 
Negatively isolated, Ly6G- cells were centrifuged 300 xg for 10 min at 4°C. The 
pellet was re-suspended in 400µl of buffer per 1x108 cells and 100µl of biotin-
conjugated αGr1 antibody was added, mixed well and incubated for 10 minutes at 
4°C. Cells were washed by adding 10ml of buffer and centrifuged at 300 xg at 4°C 
for 10 minutes. The cell pellet was re-suspended in 900µl of buffer per 1x108 and 
100µl of streptavidin-conjugated MicroBeads was added, mixed well and 
incubated for 15 minutes at 4°C. Cells were washed by adding 10ml of buffer and 
centrifuged at 300 xg at 4°C. The cell pellet was re-suspended in 500µl of buffer 
and magnetic separation was performed to positively isolate Gr1low Ly6G-. To 
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protect from clogging the cells were passed through a 30 μm cell strainer before 
applying to the MACS columns. Cells were then applied on the column connected 
to magnetic field. After washing the column remained cells were flushed with 5 ml 
MACS buffer. After the enrichment the cells were centrifuged, counted and 
processed for further application 
 
3.16 In vitro suppression assay 
Bead-isolated CD8+ T cells from naïve TCRtg mice (55) were incubated for the 
different lengths of time with F-MuLV CD8+ T cell peptide loaded onto mouse DCs 
in complete RPMI medium. The DCs were loaded with 5 μg peptide 
(AbuAbuLAbuLTVFL) for 1 hour at 37 °C. After loading, the DCs were washed, 
counted and seeded at a ratio of 1 DC to 5 CD8+ T cells. Additionally, bead-
isolated gMDSCs or mMDSCs from B6, PD-L1 KO or CD39 KO mice were 
isolated, stained with Violet Tracer dye for 20 min at 37°C followed by 
manufacturer’s instructions, and added to this setup at different concentrations. 
The cells were incubated for 3 days at 37°C with 5 % CO2. After 3 days the cells 
were harvest, stained for surface and intracellular molecules, and proliferation of 
live CD8+ cells was analyzed. The cells were re-suspended in FACS buffer and 
transferred into FACS tubes for the measurement on the LSRII.  
Additionally, for experiments that examined the effect of NO and arginase, 
described above assay was used for the characterization of gMDSCs functions in 
vitro with use of inhibitors. Besides bead-isolated CD8+ T cells from naïve TCRtg 
mice, peptide loaded DCs and Violet Tracer stained gMDSCs an arginase inhibitor 
(0.5 mM) nor-NOHA (NW-hydroxyl-nor-L-arginine) and NO inhibitor (0.5 mM) L-
NMMA were added at the beginning of the culture (193). 
 
3.17 Statistical analyses  
Statistical analyses and graphical presentations were computed with Graph Pad 
Prism version 5. Statistical differences (p-value) between two groups were 
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performed using unpaired t test. Statistical differences (p-value) between the 
different parameters were performed testing with the one-way ANOVA analysis 
with Bonferroni multiple comparison post analysis. The p-value is a probability with 
a value ranging from zero to one.  
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4. Results 
 
4.1 Myeloid derived suppressor cells expand during FV infection  
Myeloid derived suppressor cells (MDSCs) were shown to play a role in the 
suppression of immune responses not only in cancer, but also in various infectious 
diseases, such as LCMV, HCV, HBV and HIV. However their exact role in 
retroviral infections is still elusive (45-47). 
In order to characterize MDSCs during FV infection, B6 mice were infected and 
the kinetics of the MDSC response was determined. The numbers of both 
monocytic (mMDSC, Ly6G- Ly6Chigh) and granulocytic (gMDSC, Ly6Ghigh Ly6Clow) 
MDSCs were analyzed at different time points in the spleen of FV infected mice 
(Figure 4.1). mMDSCs were detectible in naïve mice and their frequency was 
about three thousand mMDSCc per one million nucleated splenocytes. This 
number of MDSCs was stable during early FV infection until day 10. At day 12 and 
14 after infection, the population of mMDSCs expanded significantly. The 
expansion of mMDSCs peaked on day 14 post infection in the spleen (Figure 4.1 
A), and the frequency of these cells reached more than 6 000 per one million 
spleen cells. gMDSC numbers also peaked on day 14 post infection, reaching 6 
000 per one million spleneocytes (Figure 4.1 B). During the chronic phase of FV 
infection, both numbers of granulocytic and monocytic MDSC were only slightly 
elevated in comparison to non-infected mice (Figure 4.1). These data indicate that 
the populations of mMDSCs and gMDSCs expanded at day 14 after FV infection, 
a time point that is concomitant with the reduction in virus-specific effector CD8+ T 
cell responses (77).  
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Figure 4.1 Kinetics of the mMDSC and gMDSC response during acute FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV or left un-infected, and MDSC 
numbers were measured using flow cytometry. Total spleen cells were analyzed at 
various time points post infection. (A) The numbers of Ly6Ghigh Ly6Clow and Ly6G- Ly6Chigh 
per 1x106 live splenocytes are displayed. At least 7 mice per group from five independent 
experiments were analyzed. Bars represent SEM of the mean. For statistical analysis an 
ANOVA multiple comparison test was carried out with the group of naïve mice as 
reference (* < 0.05, **, *** < 0.0005). 
 
Next, it was of interest whether FV can infect MDSCs. During the course of 
infection, FV infects erythroblasts, B cells, and myeloid cells. To determine 
infected MDSCs, AK720, an antibody which binds to MuLV-env gp70, was used. 
gp70+ MDSCs were found in both the monocytic and the granulocytic 
subpopulation of MDSCs at 7 days post infection (Figure 4.2 B). More mMDSCs 
than gMDSC were infected at this time point. However, while most infected 
mMDSCs subsequently disappeared from the spleen, infected gMDSCs were still 
detectable at 14 days post infection. Thus, MDSCs can be targets for FV infection.  
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Figure 4.2 Kinetics of mMDSCs and gMDSCs infection during acute FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV or left un-infected, and MDSC 
numbers were measured in the spleen at various time points post infection using flow 
cytometry. (A) The numbers of gp70+ Ly6Ghigh Ly6Clow and Ly6G- Ly6Chigh per 1x106 live 
cells in the spleen are displayed. At least five mice per group from 4 independent 
experiments were analysed. Bars represent the mean with SEM. 
 
4.2 Upregulation of molecules associated with activation and effector 
functions on gMDSCs and mMDSCs during acute FV infection 
It was previously shown that functional MDSCs express different molecules that 
were associated with the suppressive activity of these cells (45-47). PD-L1, CD80, 
NOS2 and Arg1 expression on both MDSCs populations were analyzed at the 
peak of MDSC expansion, which was day 14. PD-L1 (Program death–ligand 1) is 
a molecule expressed on a variety of cells, mostly antigen presenting cells. 
Through interaction with its receptor PD-1, PD-L1 suppresses responses of T 
lymphocytes. In various studies, PD-L1 was shown to be expressed on MDSC and 
was associated with MDSC activation (72).  
CD80, which is also expressed on various cells, such as B cells and monocytes, is 
a member of the B7 family and is a co-stimulatory molecule of T cell activation. It 
is a ligand for two receptors: CTLA-4 and CD28. While CD28 induces T cell 
activation, CTLA-4 mediates T cell suppression (72). 
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Figure 4.3 Expression of CD80 and PD-L1 molecules on the MDSCs during acute FV 
infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV or left un-infected, and the expression 
of PD-L1 and CD80 on the surface of MDSCs was measured using flow cytometry on day 
14 post infection. (A) Representative histograms and (B) frequencies of CD80 and PD-
L1high expression on the surface of Ly6Ghigh Ly6Clow and Ly6G- Ly6Chigh cells in the spleen 
at 14 dpi are displayed. At least five mice per group from three independent experiments 
were analyzed. Bars represent the mean with SEM. For statistical analysis, a student t 
test was carried out with the group of naïve mice as a reference. (* < 0.05, ** < 0.005). 
 
 
5% of the naïve mMDSCs were PD-L1high (Figure 4.3 A), and up to 30% of the 
naïve gMDSCs (Figure 4.3 C) expressed high levels of this molecule (Figure 4.3 A 
and C). During FV infection, frequencies of the PD-L1high gMDSCs increased four 
times up to 20% (Figure 4.3 C). 70% of mMDSC expressed PD-L1high on the cell 
surface, increasing 2.5 times compared to naïve mice (Figure 4.3 A). 
Approximately 10% of the mMDSCs and 20% of the gMDSCs from naïve mice 
expressed CD80 (Figure 4.3 B and D). Upon infection a mean of 25% of the 
mMDSCs and 43% of the gMDSCs expressed CD80 (Figure 4.3 D). These data 
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demonstrate that the percentages of PD-L1high and CD80+ of MDSCs increased 
during FV infection and suggest that MDSCs become active upon FV infection. 
Adenosine metabolism was shown to play an important role in many processes 
involved in homeostasis and immune regulation of T cells. CD39 (Ectonucleoside 
triphosphate diphosphohydrolase-1) is an enzyme involved in the conversion of 
ATP (Adenosine triphosphate) to ADP (Adenosine diphosphate) and AMP 
(Adenosine monophosphate), which is further metabolized by CD73 (Ecto-
5’nucleotidase) to adenosine. Both of these enzymes were shown to be involved in 
Treg mediated suppression of effector T cell responses (40).  
To further characterize MDSCs during FV infection, the CD39 and CD73 
expression, both involved in the adenosine metabolism, were analyzed. 15% of 
the naïve mMDSCs were positive for CD39, and upon infection this frequencies 
did not change. Percentages of CD39+ gMDSC from both naïve and FV infected 
mice reached 70% (Figure 4.4 A), with no difference between the distinct groups. 
Only 7% of the mMDSCs from naïve or infected mice expressed CD73, with no 
influence of the infection. 20-30% of the gMDSCs were positive for CD73 in both 
naïve and FV infected animals (Figure 4.4 B). According to this observation, the 
adenosine mechanism of immune regulation was not induced by FV infection. 
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Figure 4.4 Expression levels of CD39 and CD73 on MDSCs during acute FV 
infection. B6 mice were infected i.v. with 20 000 SFFU of FV or left un-infected, and the 
expression of CD39 and CD73 on MDSCs was measured using flow cytometry at day 14 
post infection.  Frequencies of (A) CD39 and (B) CD73 expressing Ly6Ghigh Ly6Clow and 
Ly6G- Ly6Chigh cells in the spleen are displayed. At least five mice per group from three 
independent experiments were analyzed. Bars represent the mean with SEM. For 
statistical analysis, a student t test was carried out. 
 
 
In order to investigate the function of MDSCs, it was of interest to identify whether 
the main known mechanisms of MDSCs’ mediated suppression were induced 
during acute FV infection. Arg1 was of special interest, which is an enzyme 
converting ι-arginine to urea and ι-ornithine, and NOS2, an enzyme further 
synthetizing nitric oxide (NO) and ι-citrulline (13).  
Naïve animals did not express high levels of intracellular NOS2 on MDSCs. 
However, after infection up to 15% of all mMDSCs started to express NOS2. In the 
granulocytic subset, NOS2 expression was at the same frequency as in naïve 
animals (1-1.5%) (Figure 4.5 A). Arg1 was expressed in 2-5% of gMDSCs and 
mMDSCs from naïve mice but increase to around 10% post infection (Figure 4.5 
B).   
Summarizing the phenotypic data, it can be postulated that MDSCs become 
activated during FV infection. Elevated expression of PD-L1high and CD80 may be 
associated with this activation. The expression of CD39 and CD73 on the cell 
surface of MDSCs did not change during infection. Possible mechanisms of 
mMDSC function may include nitric oxide metabolism and ι-arginine conversion by 
Arg1 
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Figure 4.5 Expression levels of Arg1 and NOS2 in MDSCs are upregulated during 
acute FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV or left un-infected and the expression 
of Arg1 and NOS2 in the MDSCs was measured using flow cytometry for spleen cells at 
day 14 post infection. Frequencies of (A) NOS2 and (B) Arg1 expressing Ly6Ghigh Ly6Clow 
and Ly6G- Ly6Chigh cells in spleen are displayed. At least five mice per group from three 
independent experiments were analyzed. Bars represent the mean with SEM. For 
statistical analysis, a student t test was carried out with the group of naïve mice as a 
reference (* < 0.05, ** < 0.005). 
 
 
4.3 5FU and αLy6G selectively deplete MDSCs 
 
After characterizing the MDSC expansion and activation it was of interest to 
confirm the suppressive role of MDSCs in vivo during an ongoing FV infection. 
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Different methods to eliminate, block or suppress MDSCs have already been 
described, including antibody treatment (αGr1, αLy6G), directly acting drugs (5-
Fluorouracil (5FU), Silendafil, doxorubicine) and drugs, which were described to 
maturate MDSCs (ATRA, CpG) (44, 50).    
In order to investigate the role of MDSCs during FV infection in living mice either 
gMDSCs or both the gMDSC and mMDSC population were depleted. By single 
administration of 5FU four days prior to sacrificing the mice on day 14 post 
infection, both MDSC populations were depleted, with an efficacy of 91% (Figure 
4.6 C). The pyrimidine analog 5FU is a cytostatic drug with MDSCs specific 
cytotoxicity. 
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Figure 4.6 Schematic of the MDSC depletion during acute FV infection in the spleen.  
B6 mice were infected i.v. with 20 000 SFFU of FV, and/or treated with 5FU or αLy6G. 
Experimental design of the MDSC depletion by administration of (A) 5FU or (B) αLy6G. 
(C) Representative dotplots of MDSC during FV infection after administration of 5FU, 
αLy6G or untreated.  
The second approach, the i.p. administration of αLy6G antibody, selectively 
depleted only gMDSCs, with a depletion efficiency of 98% (Figure 4.6 C).  αLy6G 
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antibody was administered four times every third day and organs were harvest at 
day 14 post infection.  
 
4.3.1 Depletion of MDSCs leads to a reduction in FV loads and an increase of 
cytotoxic CD8+ T cells 
 
The depletion of MDSCs was first shown in cancer models and led to a reduction 
of tumor size and activation of different immune cell subsets, primarily T cells. 
Therefore, it was of interest to investigate the influence of MDSC depletion on 
acute retroviral infection.   
The main question after the depletion of MDSCs appeared to be whether the 
reduction of these cells has an effect on viral loads and on different immune cell 
subsets. First, an Infectious center assay was performed in order to analyses the 
viral loads. After depletion of total MDSCs with 5FU (gMDSCs and mMDSCs), a 
up to 10 fold reduction in viral loads per million cells was observed. After the 
depletion of only gMDSCs a slight and not significant reduction of viral loads was 
observed (Figure 4.7 A). Replication of FV is normally associated with a mild 
splenomegaly in C57/Bl6 mice. The depletion of all MDSCs resulted in diminished 
spleen weights after administration of 5FU. The depletion of only gMDSCs with 
αLy6G antibodies likewise diminished spleen sizes (Figure 4.7B). These data 
suggest that MDSC influence numbers of FV-infected cells in vivo. 
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Figure 4.7 Depletion of MDSCs leads to a reduction in viral loads during acute FV 
infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV, and/or treated with 5FU and/or 
αLy6G, and viral loads as well as spleen weight were estimated at day 14 post infection. 
(A) The numbers of infected cells per 1x106 cells in spleen are displayed. (B) Spleen 
weights were assessed. At least five mice per group from three independent experiments 
were analyzed. Bars represent the mean with SEM. For statistical analysis an ANOVA 
multiple comparison test was carried out (* < 0.05, *** < 0.0005). 
 
Previous data show that the elimination of MDSCs led to a reduced number of 
infected cells. CD8+ T cells were shown to play a major role in the control of acute 
FV infection and reduction of viral loads during the acute phase of FV Infection 
(82). Interestingly, the contraction phase of the CD8+ T cell response at day 12 
post infection correlated with the expansion of MDSCs (77). Thus it was of interest 
whether the population of effector CD8+ T cells was influenced by MDSCs. CD43+, 
a sialoglycoprotein, expressed on the cell surface of a variety of hematopoietically 
derived cells, including T lymphocytes, is a part of the receptor-ligand complex, 
required for T cell activation (52-53). Naïve CD8+ cells do not express CD43+, but 
CD43+ becomes highly up-regulated on antigen specific effector CD8+ T cells 
(58).  Interestingly, after the depletion of all MDSCs, the frequency of CD43+ CD8+ 
T cells increased significantly, reaching levels of 20 000 CD43+CD8+ cells per one 
million spleen cells in comparison to 10 000 activated CD8+ cells per million in only 
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FV-infected mice (Figure 4.8A). After the depletion using αLy6G antibodies, higher 
frequencies of activated CD8+ T cells were observed, reaching 18 000 activated 
CD8+ T cells per one million cells. These results suggest that the depletion of 
MDSCs and the following reduction in viral loads during acute FV infection may be 
a result of an improved expansion CD8+ T cell response. 
 
Figure 4.8 Depletion of MDSC leads to an expansion of effector CD8+ T cells during 
acute FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV and/or treated with 5FU and/or αLy6G 
or left un-infected and CD8+ numbers were measured using flow cytometry for spleen 
cells at 14 days post infection. (A) The numbers of CD43+ of live CD8+ per 1x106 live cells 
in spleen are displayed. (B) The numbers of FV-DbgagL class I tetramers of live 
CD8+CD43+ cells in spleen are displayed. At least five mice per group from three 
independent experiments were analyzed. Bars represent the mean with SEM. For 
statistical analysis an ANOVA multiple comparison test was carried out (* < 0.05). 
 
Next, it was of interest whether the expanded population of CD8+ T cells was 
specific for the immunodominant epitope of Friend virus. With the use of FV-
DbgagL class I tetramers it was possible to assess that the administration of 5FU 
did not result in increased percentages of virus-specific effector CD8+ T cells. 
However, the depletion with αLy6G antibodies significantly increased the 
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frequency of tetramer+ CD8+ cells. These data imply that antibody mediated 
gMDSCs depletion leads to an expansion of virus-specific CD8+ T cells, but the 
administration of 5FU was more associated with polyclonal expansion of CD8+ 
effector cells.   
 
 
 
Figure 4.9 Increased proliferation of CD8+ T cells after MDSC depletion during acute 
FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV and/or treated with 5FU and/or αLy6G 
or left un-infected, and the CD8+ numbers were measured using flow cytometry for spleen 
cells at 14 days post infection. The numbers of Ki67+ of live CD43+CD8+ per 1x106 live 
cells in spleen are displayed. At least five mice per group from three independent 
experiments were analyzed. Bars represent the mean with SEM. For statistical analysis 
an ANOVA multiple comparison test was carried out ( *** < 0.0005). 
 
Ki67 is a nuclear protein involved in cell proliferation (18). To characterize the 
proliferation of the CD8+ T cell population upon MDSC depletion, the intranuclear 
expression of Ki67 was analyzed. During the 5FU administration almost 2000 
CD43+ CD8+ cells per million proliferated compared to the infected only group, in 
which 1300 cells were positive for Ki67+. In gMDSC depleted mice, 1600 activated 
CD8+ T cells were proliferating, however this difference was not significant (Figure 
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4.9). Thus, the depletion of MDSCs may lead to an increased proliferation of CD8+ 
cells.  
 
IL-2, IFNγ and TNFα are three cytokines produced by activated functional CD8+ T 
cells. Therefore, the cytokine profile of the CD8+ T cell population was analyzed 
after MDSC depletion. IFNγ is a very important cytokine in both the innate and the 
adaptive immune response. The main functions are the activation of macrophages 
and induction of MHC class II expression. TNFα shows a strong pro-inflammatory 
capacity with direct lytic effects on tumor cells. IL-2 stimulates the T and B cell 
proliferation, induces cytotoxicity of macrophages, and induces cytokine 
production. Expression of TNFα, INFγ and IL-2 in activated CD8+ cells after 
intracellular cytokine staining was analyzed. During FV infection around 15% of 
the CD8+ T cells expressed TNFα or IFNγ. IL-2 expression was lower at around 
8%. Depletion of total MDSCs (5FU) resulted in significant increases in the 
percentages of TNFα (up to 27%), IFNγ (up to 28%), and IL-2 (up to 15%) 
producing CD8+ T cells (Figure 4.10 A-B). In contrast, gMDSC depletion (αLy6G 
antibody) did not influence cytokine responses of CD8+ T cells. The depletion of total 
MDSCs but not gMDSCs resulted in an increased functionality of CD8+ T cells in 
terms of cytokine production.   
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Figure 4.10 Upregulation of proinflammatory cytokine expression by CD8+ T cells 
after MDSC depletion during acute FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV and/or treated with 5FU and/or αLy6G 
or left un-infected, and CD8+ numbers were measured using flow cytometry for spleen 
cells 14 days post infection. The frequencies of (A) TNFα, (B) IFNγ and (B) IL-2 of live 
CD8+ in spleen are displayed. At least five mice per group from three independent 
experiments were analyzed. Bars represent the mean with SEM. For statistical analysis, 
an ANOVA multiple comparison test was carried out with a group of naïve mice as 
reference (* < 0.05). 
 
 
Virus-specific CD8+ T cells kill FV-infected cells by releasing cytotoxic granules. 
The main cytotoxic effector molecule stored in the granule of cytotoxic CD8+ T 
cells is Granzyme B (GzmB). To further characterize effector CD8+ T cells after 
MDSC depletion, a closer look was taken at the GzmB expression by these cells. 
After depletion of the total MDSC population, the frequency of GzmB+ activated 
CD8+ T cells was almost twice as high as in the infected only group. Specific 
gMDSC depletion showed a slight, however not significant, increase in GzmB+ 
cells compared to the infected only group (Figure 4.11). Thus, only depletion of 
total MDSCs resulted in an increased cytotoxicity of CD8+ T cells. 
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Figure 4.11 Increased production of granzyme B by CD8+ T cells after MDSC 
depletion during acute FV infection.  
B6 mice were infected i.v. with 20 000 SFFU of FV and/or treated with 5FU or αLy6G or 
left un-infected, and CD8+ numbers were measured using flow cytometry for spleen cells 
at 14 days post infection. The numbers of GzmB+ of live CD43+CD8+ cells in spleen are 
displayed. At least five mice per group from three independent experiments were 
analyzed. Bars represent the mean with SEM. For statistical analysis, an ANOVA multiple 
comparison test was carried out with the group of naïve mice as reference (*** < 0.0005). 
 
To analyze whether MDSCs have an influence on CD8+ T cell killing, an in vivo 
cytotoxicity assay was performed. B6 mice were infected with FV and depleted for 
MDSCs with 5FU. On day 14 post infection all groups of mice received 
lymphocytes from naïve donor mice that were loaded with a MHC class I-
restricted, FV-specific CD8+ T cell epitope peptide and labelled with CFSE. One 
hour after i.v. injection of target cells, mice were sacrificed and the in vivo killing 
activity was quantified. It was not possible to detect any differences in the in vivo 
killing between infected and the infected MDSC depleted mice in any of the 
analyzed organs. Thus, depletion of total MDSCs did not significantly improve 
CD8+ T cells killing target cells during FV infection (Figure 4.12). 
 
Figure 4.12 Depletion of total MDSCs did not affect in vivo cytotoxicity of CD8+ T 
cells. Spleen cells from donor naïve mice were isolated and loaded with a MHC class I-
restricted FV-specific CD8+ T cell epitope peptide labelled with CFSE and injected i.v. into 
FV-infected B6 mice. Mice were treated with 5FU or left untreated One hour after i.v. 
injection of CFSE targets, mice were sacrificed and the in vivo killing activity was 
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quantified in single-cell suspensions from the spleen, lymph nodes and bone marrow. At 
least two independent experiments were analyzed.  
 
 
 
4.4 gMDSC suppress CD8+ T cell responses in vitro  
 
After characterizing MDSCs during Friend Virus infection, it was of interest to 
analyze the suppressive activity and effector mechanisms of MDSCs in an in vitro 
model.  
To achieve this goal, a CD8+ T cell proliferation assay was performed. Bone 
marrow derived dendritic cells were incubated with Violet Cell tracer labeled virus-
specific CD8+ T cells isolated from DbGagL TCR transgenic mice, of which more 
than 90% of the CD8+ T cells contained a TCR specific for the DbGagL FV epitope 
(73). The DCs were loaded with the DbGagL epitope peptide to induce virus-
specific proliferation of the CD8+ T cells. mMDSCs and gMDSCs were isolated 
from FV-infected mice and added in different cell numbers in order to determine 
the effect of these cells on the CD8+ T cell response. After 3 days, CD8+ T cell 
proliferation and GzmB expression was analyzed. At this time point an average of 
90% of the CD8+ T cells in the culture had undergone at least one cell division. 
Interestingly, this CD8+ T cell proliferation was only suppressed by gMDSCs, but 
not by mMDSCs (Figure 4.13). The suppression by gMDSCs was cell number 
dependent and a 4.5 fold reduction of proliferation was found at an effector target 
ratio of 1:10. At this ratio no significant effect of mMDSCs on the proliferation of 
FV-specific CD8+ T cell was found.  
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Figure 4.13 Granulocytic myeloid derived suppressor cells inhibited CD8+ T cell 
proliferation.  
CD8+ T cells isolated from DbGagL TCR transgene mice were incubated with dendritic 
cells loaded with MHC class I-restricted FV-specific CD8+ T cell epitope peptide and co-
incubated with either gMDSCs or mMDSCs. (A) Representative histograms and (C) 
percentages of CD8+ T cells after co-incubation with or without either gMDSC or mMDSCs 
from FV-infected mice are shown. (B) CD8+ T cell proliferation was measured after co-
incubation with different effector target rations of gMDSCs. CD8+ T cells incubated with 
peptide loaded DC serve as a positive control, CD8+ T cells incubated with non-loaded DC 
serve as negative control. At least three independent experiments were analyzed. Bars 
represent the mean with SEM. For statistical analysis, an ANOVA multiple comparison 
test was carried out with the group of naïve mice as a reference (** < 0.005). 
 
Additionally, the GzmB expression of activated CD8+ T cells was measured. An 
average of 90% of all CD8+ T cells in the cultures produced GzmB. This 
expression of GzmB was also diminished by gMDSCs, but not by mMDSCs co-
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incubation (Figure 4.14). An effector target ratio of 1:10 gMDSCs reduced the 
percentage of GzmB+ CD8+ T cells to a mean of below 20% which corresponds 
with the previously obtained results on the suppression of proliferation (Figure 
4.12).  
 
 
Figure 4.14 Granulocytic myeloid derived suppressor cells inhibited GzmB 
production by CD8+ T cells.  
CD8+ T cells isolated from DbGagL TCR transgene mice were incubated with dendritic 
cells loaded with MHC class I-restricted FV-specific CD8+ T cell epitope peptide and co-
incubated with either gMDSCs or mMDSCs. Frequencies of GzmB expressing 
CD43+CD8+ cells after incubation of CD8+ cells with gMDSCs or mMDSCs from FV-
infected mice are shown. Bars represent the mean with SEM. For statistical analysis, an 
ANOVA multiple comparison test was carried out (*** < 0.0005). The experiment was 
repeated five times with comparable results. 
 
These data suggest that gMDSC but not mMDSCs from FV-infected mice were 
able to suppress virus specific CD8+ T cell responses in vitro.  
 
4.4.1 gMDSC suppression of CD8+ T cells was blocked by arginase or NO 
inhibition  
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Different mechanisms of MDSC suppression were described, among them the 
pathways of L-arginine metabolism. There are two enzymes essential for this 
process. Arg1 converts ι-arginine to urea and ι-ornithine. This is followed by 
NOS2, which metabolizes substrates to nitric oxide (NO) and ι-citrulline (13). 
These two enzymes play an important role in ι-arginine metabolism.. As shown 
above, during FV infection, the expression of Arg1 in gMDSCs increased but the 
expression of NOS2 on gMDSCs was not altered (Figure 4.4). mMDSC expression 
of both Arg1 and NOS2 was augmented during FV infection (Figure 4.4). 
In order to investigate whether CD8+ T cell suppression is arginase or NO 
dependent, the previously described proliferation assay was used. Additionally, 
nor-NOHA, which is a pan arginase inhibitor, or L-NMMA, a pan NO inhibitor, were 
used. After administration of the arginase inhibitor, we observed an approximately 
2.5 times higher percentage of proliferating CD8+ T cells in the presence of 
gMDSCs in comparison to the untreated control. Administration of the NO inhibitor 
led to an almost 3 times higher percentage of proliferating CD8+ T cells compared 
to the untreated group.(Figure 4.15). These data suggest that ι-arginine 
metabolism is at least one mechanism of gMDSCs mediated suppression of T cell 
proliferation in vitro.  
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Figure 4.15 Suppression of nitric oxide and arginase partially restored CD8+ T cell 
proliferation.  
CD8+ T cells isolated from DbGagL TCR transgenic mice were incubated with dendritic 
cells loaded with MHC class I-restricted FV-specific CD8+ T cell epitope peptide and co-
incubated with gMDSCs with or without addition of L-NMMA or nor-NOHA. (A) 
Representative histograms and (B) percentages of CD8+ T cell proliferation after co-
incubation with or without gMDSCs in the presence or absence of L-NMMA/nor-NOHA are 
shown. At least three independent experiments were analyzed. Bars represent the mean 
with SEM. For statistical analysis, an ANOVA multiple comparison test was carried out (*** 
< 0.0005). 
 
 
4.4.2 gMDSC suppression of CD8 T cells was partially abrogated when 
MDSC lacked PD-L1 
 
PD-1 (Programmed cell death receptor-1) is a well-characterized receptor involved 
in the suppression of immune response of virus-specific T cells (42). By binding 
with its ligand, PD-L1, PD-1 expressing T cells become dysfunctional or 
“exhausted”. PD-L1 is expressed on a variety of cells, including MDSCs (25). As 
shown above, the expression of PD-L1 on MDSCs increased during FV infection 
(Figure 4.3). Therefore, it is of interest to analyze whether PD-L1 plays a role in 
MDSC mediated suppression.  
To analyze the role of PD-L1 during the T cell suppression by gMDSCs, the 
previously described proliferation assay was used. For this experiment, gMDSCs 
were isolated from FV-infected PD-L1 knockout mice.  
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Figure 4.16 Lack of PD-L1 or CD39 partly restored CD8+ T cell proliferation        
CD8+ T cells isolated from DbGagL TCR transgenic mice were incubated with dendritic 
cells loaded with MHC class I-restricted FV-specific CD8+ T cell epitope peptide and co-
incubated with gMDSCs isolated from PD-L1 KO or CD39 KO mice. (A) Representative 
histograms and (B) percentages of CD8+ T cells after co-incubation with or without 
gMDSCs isolated from B6, PD-L1 KO or CD39 KO FV infected mice are shown. At least 
three independent experiments were analyzed. The bars represent the mean with SEM. 
For statistical analysis, an ANOVA multiple comparison test was carried out (*** < 0.0005). 
 
Interestingly, gMDSCs lacking PD-L1 were not able to efficiently suppress CD8+ T 
cell proliferation in vitro (76% of all CD8+ T cell proliferated) in contrast to  PD-L1 
expressing gMDSCs (25% proliferation rate) (Figure 4.16). This suggests the 
importance of PD-L1 in gMDSC mediated CD8+ T cell suppression. 
Adenosine metabolism plays an important role in maintaining immune 
homeostasis. CD39 (Ectonucleoside triphosphate diphosphohydrolase-1), an 
enzyme involved in the conversion of ATP to ADP and AMP, was shown to have a 
role in the effector T cell suppression mediated by regulatory T cells. Therefore, it 
was of interest to investigate whether adenosine metabolism may also be involved 
in MDSC mediated immune suppression.   
The previously described CD8+ T cell proliferation assay was again used to 
answer this question. After incubation of gMDSCs isolated from CD39 KO mice 
with CD8+ T cells, 64% of the CD8+ T cells had undergone cell division, which was 
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almost 2.5 higher as in the control group with gMDSCs from wild type mice (Figure 
4.16). These data suggest a significant role of adenosine metabolism in gMDSC 
mediated suppression.   
 
The first part of this thesis concentrated on MDSCs and their function during acute 
FV infection. We observed an expansion of both gMDSCs and mMDSCs at day 14 
post infection and they also showed a higher expression of PD-L1high, CD80, Arg1 
compared to naïve mice. Further, we were able to show that mainly FV-activated 
gMDSCs but not mMDSCs were able to suppress virus-specific CD8+ T cell 
responses in vitro. Moreover, in vivo depletion of MDSCs resulted in a reduction of 
viral loads and in augmented cytotoxic CD8+ T cell responses. As mechanisms of 
gMDSC mediated suppression of virus-specific T cell proliferation in vitro NO or 
arginase metabolism as well as PD-L1 and CD39 expression were identified. 
These data demonstrate the importance of MDSCs in the regulation of CD8+ T cell 
responses during acute retroviral infection and identify mechanisms involved in the 
suppressive function of these cells.  
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5 The interaction of inhibitory mechanisms: MDSCs, T regulatory cells 
(Tregs) and inhibitory receptors. 
The immune response to acute viral infection is restrained by different 
mechanisms such as MDSCs, Tregs or inhibitory receptors to prevent severe 
immunopathology by overshooting T cell responses. All of these mechanisms 
were shown to work independently. Recently, immune therapies involving immune 
checkpoint blockers are gaining increasing attention. However, the interactions 
between the different suppressor mechanisms are not very well studied. 
Therefore, the question arises what influence the depletion or blockage of one of 
these mechanisms may have on the quality and quantity of the other inhibitory 
mechanisms.   
5.1 Regulatory T cell responses during MDSC depletion 
Another important mechanism of suppressing immune responses is the activity of 
Tregs. Previous work showed the importance of the Treg mediated inhibition of T 
cells in acute and chronic FV infection (137).     
During the depletion of MDSCs in FV-infected mice, an increase of Tregs was 
observed. In naïve mice approximately 10% of CD4+ cells are Foxp3+.  In FV-
infected mice approximately 17% of the CD4+ T cells are Foxp3+ Tregs, whereas 
animals depleted for total MDSCs (5FU) had up to 25% of Tregs and αLy6G 
treated mice 22% (Figure 5.1 A). After MDSC depletion we found a slight increase 
in Treg proliferation (Ki67+), but this was not statistically significant (Figure 5.1B). 
This result shows that indeed different immune checkpoints influence each other 
and the question arose how the MDSC response is altered during FV infection if 
Tregs are depleted and/or inhibitory receptors are blocked.  
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Figure 5.1 Tregs expand upon MDSCs depletion in FV-infected mice  
B6 mice were infected i.v. with 20 000 SFFU of FV or left un-infected, and Tregs 
frequencies were measured using flow cytometry for spleen cells at 14 days post 
infection. (A) The frequencies of FoxP3+ of live CD4+ in spleen are displayed. (B) The 
frequencies of Ki67+ of live FoxP3+CD4+ in spleen at 14 dpi are displayed. At least five 
mice per group from three independent experiments were analyzed. Bars represent the 
mean and SEM. For statistical analysis, an ANOVA multiple comparison test was carried 
out (* < 0.05, ** < 0.005,). 
 
 
To answer this question, a DEREG mouse model was used for the selective 
depletion of Tregs, and MDSC numbers were assessed. After Treg depletion, 
almost 4-times higher frequencies of mMDSCs (Figure 5.2 A) and 2-times of 
gMDSCs, compared with infected non-depleted mice, were observed (Figure 5.2 
B).  The expanded populations of gMDSCs also showed slightly increased 
percentages of CD80+ and PD-L1high cells (Figure 5.3 A). This increase in CD80 
and PD-L1 expressing cells was even more pronounced in the mMDSC population 
after Treg depletion (Figure 5.3 B).    
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Figure 5.2 Depletion of Tregs led to MDSC expansion in FV-infected mice  
DEREG mice were infected with 20 000 SFFU of FV and depleted for Tregsand MDSC 
numbers were measured using flow cytometry for spleen cells at 14 days post infection. 
The numbers of (A) mMDSCs and (B) gMDSCs per 106 living cells in spleen at 14 dpi are 
displayed. At least five mice per group from three independent experiments were 
analyzed. Bars represent the mean and SEM. For statistical analysis, an ANOVA multiple 
comparison test was carried out (* < 0.05, ** < 0.005). 
 
 
Notably, the loss of one suppressive mechanism led to a compensatory 
mechanism for another inhibitor. Depletion of MDSCs resulted in the expansion of 
Tregs during acute FV infection. Similarly, the depletion of Tregs resulted in an 
activation of MDSCs.  
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Figure 5.3 Characterization of MDSCs after Treg depletion during acute FV 
infection. 
DEREG mice were infected with 20 000 SFFU of FV, treated with diphtheria toxin or left 
un-treated, and the expression of PD-L1high and CD80 on the surface of MDSCs was 
measured using flow cytometry. (A) Frequencies of CD80 and PD-L1 expression on the 
surface of Ly6Ghigh Ly6Clow and Ly6G- Ly6Chigh cells in spleen at 14 dpi are displayed. At 
least five mice per group from three independent experiments were analyzed. Bars 
represent the mean with SEM. For statistical analysis, an ANOVA multiple comparison 
test was carried out with the group of naïve mice as reference (* < 0.05, ** < 0.005, *** < 
0.0005). 
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5.2 Combination of MDSC and Treg depletion  
 
As shown in the previous chapter, the depletion of one inhibitory cell population 
led to compensatory mechanisms. The question arises whether the simultaneous 
depletion of different inhibitory cell populations may lead to a stronger activation of 
effector mechanisms as well as a reduction of viral loads. In order to answer this 
question, both gMDSC and Tregs were simultaneously depleted during FV 
infection and mice were analyzed on day 14 post infection. Interestingly, the 
reduction in viral loads was higher in Treg plus gMDSC depleted animals than in 
only Treg or gMDSC depleted mice, however this difference was not significant 
(Figure 5.4 A). Moreover, after the depletion of the two regulatory cell populations, 
the frequencies of activated, virus specific CD8+ T cells significantly increased 
compared to mice depleted for Tregs. (Figure 5.4 B).  
 
 
 
Figure 5.4 Combination of gMDSCs and Tregs depletion leads to a reduction in viral 
loads and increased numbers of activated virus specific CD8+ T cells.  
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DEREG mice were infected with FV, and/or treated with DT and/or αLy6G, and an IC 
assay was performed and CD8+ T cell numbers were analyzed. (A) The numbers of 
infected cells per 1x106 cells in the spleen are displayed. The numbers of (B) Tetr+ or (C) 
GzmB+ of live CD43+CD8+ in the spleen at 14 dpi are displayed. Bars represent the mean 
with SEM. For statistical analysis, an ANOVA multiple comparison test was carried out 
with the group of naïve mice as reference (* < 0.05, ** < 0.005, *** < 0.0005). 
 
However, it is important to notice that on the last day of the experiment, animals 
were starting to experience light health disturbance, their fur was slightly 
unpolished and matt, and the movements were slower compared to animals 
treated with DT or αLy6G. Therefore, it is of importance to further investigate the 
combination treatment of gMDSCs and Tregs depletion, with regard to the 
development of immunopathology. These results suggest that combination therapy 
with depletion of gMDSCs and Tregs might improve immune responses and be 
may considered as immunotherapy for retroviral infection. However, it is crucial to 
further investigate this topic. 
 
5.3 Combined blockage of inhibitory receptors with Treg depletion 
 
We have previously shown that a combination therapy which blocks the inhibitory 
receptors PD-1 and Tim-3 reduces viral loads and restores CD8+ T cell responses 
in chronic FV infection (137).  
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Figure 5.5 Treatment of acute FV infection with αPD-L1, αTim3 and depletion of 
Tregs. Schematic representation of the experiment. Shortly, DEREG mice were infected 
with 20 000 SFFV FV + LDV, treated with DT and αPD-L1, αTim3 in combination or alone 
or left untreated. On day 18 post infection spleen, bone marrow, peripheral lymph nodes, 
and intestinal lymph nodes were harvest for further analysis. 
 
It was of interest weather a combination therapy targeting two checkpoint blockers 
(inhibitory receptors and Tregs) would affect the MDSC and T cell response in 
acutely FV infected mice. First, viral loads were analyzed after combination 
therapy. At day 14 post infection an average of 5000 cells per million splenocytes 
were infected in mice inoculated with FV. Treg depletion or antibody therapy 
reduced this viral load to 50 to 100 infected cells per million. Interestingly, 
combination treatment resulted in a further reduction of viral loads to around 20 
infected cells per million (Figure 5.6). These results suggest that the simultaneous 
blocking of different inhibitory mechanisms may further reduce viral loads and 
improve the therapy outcome.  
 
Figure 5.6 Depletion of Tregs combined with blocking inhibitory receptors leads to 
reduction of viral loads during acute FV infection.  
Shortly, DEREG mice were infected with FV + LDV and treated with DT, αPD-L1, αTim3 in 
combination or alone, or left untreated, and infectious center assay was performed on day 
14 post infection. The numbers of infected cells per 1x106 cells in spleen are displayed. At 
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least five mice per group from three independent experiments were analyzed. Bars 
represent the mean with SEM. For statistical analysis, an ANOVA multiple comparison 
test was carried out (* < 0.05, ** < 0.005). 
 
 
 
Figure 5.7 CD8+ T cell responses during acute FV infection after Treg depletion 
combined with αPD-L1 and αTim3 treatment.  
DEREG mice were infected with FV + LDV, treated with DT, αPD-L1, αTim3 in 
combination or alone, or left untreated. Numbers of (A) CD43+ CD8+ and (B) 
CD8+Tetramer+ of one million spleen cells at 14 dpi are displayed. At least five mice per 
group from three independent experiments were analyzed. Bars represent the mean and 
SEM. For statistical analysis, an ANOVA multiple comparison test was carried out (* < 
0.05, ** < 0.005). 
To investigate the immune response during combinatorial treatment, we had a 
closer look at different populations of T cells. Frequencies of activated CD8+ T 
cells increased upon treatment, reaching the highest values during combination 
treatment at more than 80 000 CD43+ CD8+ cells per million, however, the 
difference to only FV infected mice was not significant (Figure 5.7 B). After 
combination treatment, we were also able to observe increased frequencies of 
virus-specific CD8+ T cells in comparison to the group of only infected mice. Even 
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though the results for the combination therapy group were not significantly 
different compared to the groups with single treatment they always had the highest 
values (Figure 5.7 A). Further, the cytotoxic effector function of T cells was of 
interest. Combination therapy significantly increased the percentage of GzmB+ 
CD8+ T cells in comparison to all other groups, reaching up to 40% of all CD8+ 
spleen cells. Similarly, we observed a very strong increase in the percentage of 
GzmB+ CD4+ T cells after combination treatment during acute FV infection. Thus, 
the combination treatment resulted in augmented cytotoxic CD8+ and CD4+ T cell 
response. 
 
 
 
Figure 5.8 Percentage of CD8+GzmB+ and CD4+GzmB+ T cells after Treg depletion 
combined with αPD-L1 and αTim3 treatment during FV infection.  
DEREG mice were infected with FV + LDV, treated with DT, αPD-L1, αTim3 in 
combination or alone, or left untreated. The frequencies of (A) GzmB+ CD8+ and (B) 
GzmB+ CD4+ from spleen cells at 14 dpi are displayed. At least five mice per group from 
three independent experiments were analyzed. Bars represent the mean and SEM. For 
statistical analysis, an ANOVA multiple comparison test was carried out (* < 0.05, ** < 
0.005). 
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5.4 Combined depletion of Tregs and PD-L1 and Tim3 blocking leads to 
massive expansion of MDSC  
 
During combination treatment for depletion of Tregs and blocking of PD-L1 and 
Tim3 during acute FV infection an expansion of potentially cytotoxic CD8+ and 
CD4+ T cells was observed. As MDSC may try to counter-regulate these T cell 
responses MDSC populations were analyzed in the spleen and small intestine 
after combination therapy. On day 18 post FV + LDV infection, an expansion of 
mMDSCs and gMDSCs was observed which was most predominant after 
combination treatment. Only for mMDSC in the spleen the expansion was similar 
between mice that received combination therapy and those that were only Treg 
depleted (Figure 5.9 A and B). In the small intestine the expansion of both MDSC 
populations after combinatorial treatment was most dramatic (Figure 5.9 C). 
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Figure 5.9 MDSC expansion after Treg depletion combined with αPD-L1 and αTim3 
treatment.  
DEREG mice were infected with FV + LDV, treated with DT, αPD-L1, αTim3 in 
combination or alone, or left non-treated. (A) Representative dot plots of splenic gMDSCs 
and mMDSCs are displayed. The numbers of gMDSCs and mMDSCs of (B) spleen and 
(C) small intestine are displayed. At least five mice per group from three independent 
experiments were analyzed. Bars represent the mean with SEM. For statistical analysis, 
an ANOVA multiple comparison test was carried out with the group of naïve mice as a 
reference (* < 0.05, ** < 0.005). 
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The gMDSCs that expanded during combination treatment were further analyzed 
for activation and functional markers. The percentages of CD80+ gMDSC after 
combination treatment were significantly higher compared to FV-infected mice, 
reaching over 60% of all MDSCs. No significant difference was found for PD-L1high 
and Arg1 expression of gMDSCs between the groups (Figure 5.10). 
Treatment by depletion of Treg and blocking of αPD-L1 and αTim3 may result in 
the expansion of MDSCs, as a compensatory mechanism to counter-regulate T 
cell responses 
 
 
Figure 5.10 Characterization of gMDSCs after Tregs depletion combined with αPD-
L1 and αTim3 treatment. 
DEREG mice were infected with FV + LDV, treated with DT, αPD-L1, and αTim3 in 
combination or left untreated. Bars represent mean frequencies (with SEM) of CD80, PD-
L1high and Arg1 expression of gMDSCs from spleen. For statistical analysis, an ANOVA 
multiple comparison test was carried out with the naïve group as a reference (** < 0.005). 
 
5.5 Newly expanded population of MDSCs suppresses CD8 T cell responses 
 
Interestingly, after combination treatment a new population of MDSCs was 
observed, expressing low levels of CD11b and Gr1 (Figure 5.11 A). For this 
experiment the spleen cells were pre-isolated with Cd19+ B cells (MACS 
technology) from mice treated with DT, αPD-L1 and Tim3. The cells were sorted 
on the basis of FITC and APC fluorescence. The separation of the Gr1high CD11b+  
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and Gr1+ CD11bdim cells was performed on a FACSDiVa cell-sorter (Becton 
Dickinson, San Jose, CA). Gr1 was excited with a 488 nm laser wavelength and 
fluorescence was measured through a 585/42 nm bandpass filter. CD11b was 
excited with a 650nm laser wavelength and fluorescence was measured through a 
694/42 nm bandpass filter For each experiment 200.000–330.000 cells were 
sorted by flow cytometry.  
After the separation of the cells the purity of the separated cell populations was 
always analyzed again by flow cytometric analysis of 10.000 cells. To >95% pure 
populations of Gr1high CD11b+ or Gr1+ CD11bdim cells was achieved.  The cells 
were then and co-incubated with CD8+ T cells in the previously described 
suppression assay in different effector target ratios. Interestingly, we observed that 
CD8+ T cell proliferation was already suppressed by a lower ratio of the CD11bdim 
population in comparison to gMDSCs (Figure 5.11 B). This may suggest that the 
absence of other inhibitory mechanisms results in the compensatory appearance 
of a new CD11bdim population of MDSCs with higher suppressor functions. 
 
Figure 5.11 Newly expanded Gr1+ CD11bdim population suppressed CD8+ T cell 
proliferation. 
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CD8+ T cells isolated from TCRtg mice were incubated with dendritic cells loaded with 
MHC class I-restricted FV-specific CD8+ T cell epitope peptide and co-incubated with Gr1+ 
CD11bdim or gMDSCs isolated from DEREG mice infected with FV + LDV, treated with DT, 
αPD-L1, and αTim3 in combination. (A) A representative dotplot of Gr1+ CD11bdim after 
treatment with DT, αPD-L1 and αTim3 isolated at day 18 post FV infection. (B) 
Representative histograms for CD8+ T cell proliferation after co-incubation with Gr1+ 
CD11bdim or gMDSCs at different ratios to CD8+ T cells. As a control group CD8+ cells 
without gMDSCs were used.  
 
In current work we show a compensatory response of different inhibitory 
mechanisms during an acute retroviral infection. The depletion of one of inhibitory 
mechanism resulted in the expansion and increased activation of different 
inhibitory mechanism. Results presented in this thesis show the importance of 
inhibitory mechanisms in the immune response against retroviral infection.  
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6. Discussion 
Myeloid derived suppressor cells play an important role in regulating the immune 
response. Their influence may be beneficial, as they limit immune responses in 
order to prevent tissue damage via cell cytotoxicity. On the other hand, they may 
be suppressing immune responses against retroviral infections, which results in 
inability to completely eliminate the virus and, consequently, establishment of 
chronicity (40). The exact mechanisms controlling the impact of MDSCs on 
different cell types are not fully understood. Therefore, it is of immense importance 
to define the mechanisms and functions of MDSCs in order to find a better way to 
modulate immune responses, and to further develop immunotherapies for 
retroviral infections.  
The work presented in this thesis demonstrates the influence of MDSCs on 
cytotoxic CD8+ T cells during an acute FV infection. MDSCs expanded during the 
late phase of acute FV infection (Figure 4.1), which was correlated with CD8+ T 
cell dysfunction (27). Additionally, we found suppression of FV-specific, cytotoxic 
CD8+ T cells by the gMDSC subpopulation (Figure 4.12). We also showed the 
important role of PD-L1 and arginase in the suppression process. Finally, we 
observed interplays between different inhibitory mechanisms, such as Tregs and 
inhibitory receptors and their ligands. Moreover, blocking of these two 
mechanisms resulted in the expansion of MDSCs with a new CD11bdim phenotype, 
which showed strong suppressive activity against CD8+ T cell proliferation.   
Under normal conditions, common precursors of myeloid cells develop into mature 
myeloid cells. Under pathological conditions, these cells may not fully mature and 
start to develop inhibitory functions. This population of immature myeloid cells 
showing robust suppressive activity is known as MDSCs (41, 45,). Since MDSC is 
a recently discovered population, studies upon these cells are controversially 
discussed and various aspects, including phenotypic and functional 
characterization differ depending on experimental models (39, 47, 52). The 
commonly used gating strategy for murine MDSCs is based on co-expression of 
the markers CD11b and Gr1. The subpopulations of MDSCs, monocytic and 
granulocytic, are distinguished by high or dim expression of the Gr1 marker. 
Initially, identification by these two markers was useful. However, exact 
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characterization of mMDSCs and gMDSCs may encounter obstacles due to the 
blurred line between high and low expression of Gr1 in these two populations. In 
order to more precisely distinguish the gMDSC and mMDSC population, use of 
two Gr1 epitopes: Ly6C and Ly6G was proposed: gMDSCs are defined as CD11b+ 
Ly6G+ and Ly6C-, and mMDSCs are characterize as CD11b+ Ly6G- Ly6C+. The 
Gr1 marker was used by several groups together with Ly6C and Ly6G in one 
panel. However, simultaneous use of the Gr1 and Ly6G may lead to incorrect 
MDSCs numbers due to competition of specific antibodies for Gr1 epitopes (121). 
One difficulty is the correct characterization of MDSCs, since they share many 
markers with other cell types, especially myeloid precursor cells and neutrophils 
(45, 46). gMDSCs share an important marker with neutrophils, which is Ly6G. This 
may cause difficulties in distinguishing both populations (46). Neutrophils are 
classically described as a short-lived, homogenous cell type and their role is 
restricted to the elimination of pathogens during the innate immune response. In 
numerous publications, gMDSC populations are called neutrophil like MDSCs (21) 
or MDSCs like neutrophils (20, 21), indicating their similar, if not identical 
characteristics.  
In this study we characterize MDSCs by using antibodies against CD11b+, 
Ly6G+ and Ly6C+. It was also of importance to distinguish MDSC subpopulations, 
since it has been shown that they possess distinct functions. MDSCs were also 
characterized by PD-L1, CD80, as well as functional markers Arg1 and NOS2. The 
described strategy allows to precisely distinguish the MDSC subtypes in mice. 
Only in experiments with combination therapy, due to appearance of CD11bdim 
population, the Gr1+CD11b+ strategy was used. Additionally, to correctly define the 
MDSC populations it is important to assess their suppressive activity, as well as 
biochemical and molecular markers described for MDSCs. Thanks to this attempt 
one may be sure the correct population of MDSCs is characterized. 
Expansion of MDSCs was previously observed in various experimental models. 
Recent studies suggest that MDSC may serve as a prognostic marker for disease 
progression in various cancer models as well as during viral infections. The main 
aim of this thesis was to characterize MDSC during an acute retroviral infection of 
mice. In this study we could show an expansion of gMDSCs on day 14 post 
Discussion 
 
 
92 
 
infection and of mMDSCs between day 12-14 post infection (Figure 4.1). Elevation 
of MDSC numbers was also observed in blood of chronic HCV patients (54, 87, 
105, 159), as well as during human (53, 104, 143) and murine HBV infection (29). 
The total MDSC population as well as only gMDSCs was shown to be increased in 
numbers in HIV infection (5, 110, 142).  
Chronic infections expand MDSCs with immune suppressive activity, as T cell 
responses were found to be suppressed by MDSC in HIV, HBV and HCV infection 
(47-49). Most studies conducted in viral infections evaluated the whole 
Gr1+CD11b+ MDSCs population, without distinguishing between different 
subpopulations (5, 142). However, the effects of MDSC subpopulations on 
immune responses may vary significantly. The question remained which 
subpopulation of the MDSCs is mainly involved in restricting T cell responses in 
retroviral infections. Our current study demonstrates the suppressive impact of 
gMDSCs on CD8+ T cells in acute Friend virus infection, whereas mMDSCs were 
less effective. In contrary to our findings, mMDSCs were able to suppress the T 
and B cell response in a model of murine LP-BM5 retrovirus infection (63,64). The 
different results might be explained by technical differences in the T cell 
proliferation assay used in both studies. While we stimulated virus-specific T cells 
with its cognate antigen presented by DCs, a physiological way of inducing T cell 
proliferation and differentiation, Robertson et al., used a non-specific stimulation of 
T cells with CD3 and CD28. It was already reported that mMDSCs mainly 
suppress polyclonally activated T cells, as shown in tumor models (184) and in 
different infections such as LP-BM5, LCMV, HBV, HCV (46-49). On the other hand 
antigen-specific suppression of T cells was associated with gMDSCs function 
(183). Thus, gMDSCs may have a significant influence on disease progression in 
various cancer diseases, including multiple melanoma (149), hepatic inflammation 
and fibrosis (155), and in HIV infection (142).  
 
An activation of MDSCs has been associated with expression of different 
molecules. CD80, PD-L1, CD73, CD39, CD270, CD62L are just a few markers 
which were shown to be expressed on the cell surface of MDSCs and were linked 
to an activation of these cells (45-52). In the current study we analyzed the 
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expression of PD-L1 and CD80 as markers associated with the activation of 
MDSCs. An upregulated PD-1 expression on virus-specific CD8+ T cells in 
chronically infected mice was shown to be involved in the development of CD8+ T 
cell dysfunction. It has previously been shown that the ligand PD-L1 is expressed 
on the cell surface of activated MDSCs and might be associated with their 
suppressive potential (20). Both gMDSCs and mMDSCs showed an increased 
expression of PD-L1 upon FV infection (Figure 4.3). These results may be 
associated with the suggested role of the PD-1/PD-L1 pathway in MDSC-mediated 
immunosuppression. This possibility was proposed in various diseases, e.g. 
multiple melanoma (116) as well as in HIV (140). Vollbrecht et al. illustrated the 
role of PD-1/PD-L1 signaling in suppression mediated through HIV expanded 
gMDSC (43). The functional role of PD-L1 in MDSCs mediated CD8+ T cell 
suppression was determined in an in an in vitro analysis of CD8+ T cell 
proliferation. MDSCs used for this study lacked PD-L1, and were not able to 
suppress CD8+ proliferation as efficiently as gMDSCs expressing PD-L1 control 
group (Figure 4.15). However, more studies are required to determine the exact 
role of PD-L1 in MDSC mediated immunosuppression.  
CD80 was analyzed as an additional marker associated with MDSC activation and 
suppression. Expression of CD80 on MDSCs increased during FV infection 
(Figure 4.3). There are two different receptors for CD80, which differ in 
functionality. Binding of CD80 to the co-stimulatory receptor CD28, together with 
the T cell receptor (TCR)-CD3 complex, may generate cell-activating signal. CD28 
is expressed predominantly on naïve and early activated T cells. On the other 
hand, the binding of CD80 to CTLA-4 may deliver inhibitory signals. CTLA-4 is 
expressed by subset of late- and post-activated T lymphocytes (93, 147). CD80 
was shown to be a possible inhibitory mechanism involved in T cell suppression, 
e.g. in Cutaneous T cell Lymphoma (172). The importance of CD80 in MDSC 
function was suggested in 2008 in melanoma studies (153) and was confirmed in 
the following years (58-59). In our study we found increased frequencies of CD80 
expressed on mMDSC and gMDSC, however the exact role of CD80 in MDSC 
mediated immunosuppression should be closer characterized. 
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The phenotypic characterization of MDSCs can be challenging, therefore their 
functional properties should be the focus of attention. In the current work, MDSCs 
were functionally characterized by the expression of NOS2 and Arg1, as well as by 
the use of a virus-specific T cell proliferation assay. Expression of NOS2 increased 
only in mMDSCs, but not in gMDSCs. Arg1 expression increased in both gMDSCs 
and mMDSCs upon FV infection (Figure 4.3). These two important mechanisms of 
MDSC mediated immunosuppression are connected to ι-arginine metabolism. 
Both arginase and NO inhibitors were used in the current study in order to confirm 
the mechanism of gMDSC mediated immunosuppression of CD8+ T cells. Both, L-
NMMA, as well as nor-NOHA, partially restored the CD8+ T cell proliferation in 
vitro. Although the NO inhibitor was able to partially restore the gMDSC mediated 
suppression of CD8+ T cell proliferation, our previous results showed no 
expression of NOS2 on gMDSCs (Figure 4.4). However, it is important to note the 
existence of two different enzymes involved in to nitric oxide metabolism: NOS1 
and NOS3 (173). The expression and activity of NOS3 was reported to play a role 
in gMDSC function in the murine model of malignant tumors (174). Thus, NOS3 
might also be involved in suppression by virus induced gMDSCs, which has not 
been studied so far.  
Adenosine metabolism with the two cell-surface enzymes CD39 and CD73 is 
involved in the regulation of T cell responses (18). Their significance in Treg 
mediated immunosuppression (17) has been demonstrated. During FV infection 
both CD39 and CD73 were expressed on the cell surface of MDSCs. However, the 
level of expression did not differ between MDSCs from infected and uninfected 
mice (Figure 4.4). It has been shown that the activity of CD39, but not of CD73, 
has been important in MDSCs-mediated immunosuppression of T cells in vitro in 
the murine melanoma model (38). However, this has not been investigated in viral 
infections so far. In this study, we were able to demonstrate that CD39 contributed 
to the MDSC mediated suppression of CD8+ T cell proliferation in vitro in retroviral 
infection (Figure 4.15). 
 
Different attempts to study the function of MDSCs in vivo have been presented. 
First, transfer experiments were performed, in which freshly isolated, 
Discussion 
 
 
95 
 
lipopolisaccharid (LPS) or IFNγ induced MDSCs were transferred into recipient 
mice. This attempt was shown to inhibit inflammation (147) and reduce CD8+ T 
cell responses in a melanoma model (128). Another approach to study the function 
of MDSCs in vivo is a specific depletion of these cells. There are different ways to 
modulate MDSC by reduction of numbers or blockade of the function of MDSCs in 
vivo. The most commonly used way of depletion is by administrating αLy6G or 
αGr1 antibodies into mice. This procedure allows the efficient depletion of all 
MDSCs (αGr1 antibody) or of granulocytic MDSCs only (αLy6G antibody). 
Nevertheless, as lately shown, long term administration of either αGr1 or αLy6G 
antibody leads to reappearance of immature Ly6G+ cells (45).  
The modulation of immune responses offers promising results for the therapy of 
different diseases, including cancer and viral infections. As a recently observed 
population, MDSCs give encouraging prospects for future treatments of viral 
infections. Different methods were described to deactivate or deplete MDSCs, as 
well as differentiate them into mature cells or block their development (44-50). 
Many of these agents, like 5-Fluorouracil (5FU), ATRA, PDE-5 inhibitors, NO-
aspirins, CSF-1R inhibitors, Zoledronic Acid, JAK/STAT3 inhibitors and Multi-
Kinase inhibitors, as well as VEGF inhibitors, are already under clinical 
investigation in cancer treatment (46). Nonetheless, it is important to note the 
influence of these immunomodulatory methods on different immune cells. 
Moreover, different therapeutic drugs already used in the clinic for treatment of 
various diseases, such as cytotoxic agents, vitamins or modulators of the cell 
signaling, are shown to regulate MDSCs (46). Similarly, different medicaments 
were described to interfere with different immune cells and have an influence on 
the immune response (161). Therefore, it is of immense importance to carefully 
plan and apply a combination of different therapies in order to achieve possible 
therapeutic success without overstimulating and burdening the immune system . 
In the current study, MDSC function was investigated by using αLy6G antibody, 
which selectively depletes gMDSC, and the use of 5FU, an anti-cancer drug 
known for selectively depleting all MDSCs. Both αLy6G and 5FU administration 
resulted in the depletion of MDSCs and led to an expansion of activated CD8+ T 
cells and Tregs. Although both depletion attempts have proven to be MDSC 
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specific, it is important to note that αLy6G is also used for the depletion of 
neutrophils, and that 5FU appears to be cytotoxic in higher concentration. 
Therefore, further studies and different immunomodulation attempts are necessary 
to precisely investigate MDSCs in vivo.   
The current study shows the interaction between MDSCs and Tregs during acute 
retroviral infection. Depletion of MDSCs resulted in an increased Treg expression, 
whereas Treg depletion led to growth of MDSCs numbers (Figure 5.2). Interaction 
between MDSCs and Tregs was first suggested by Yang et al in 2006 in an 
ovarian cancer model (152). Two years later, Borello and colleagues observed that 
MDSCs may induce Treg expansion, and MDSC depletion led to a suppressed 
Treg proliferation in the B cell lymphoma model (153). Since then several of 
studies have been investigating the interactions between MDSCs and Tregs. Most 
of them confirm the expansion of Tregs, as well as their de novo generation by 
MDSCs, through TGFβ dependent and independent mechanisms. (154-158). In 
viral infections the interaction between MDSCs and Tregs was observed so far in 
HCV (161), HBV (142) and murine retrovirus induced immunodeficiency (162).  
HCV induced mMDSCs from PBMCs led to the expansion of Tregs in vitro and the 
depletion of mMDSCs resulted in the reduction of Tregs in PBMCs (107).  
Inhibitory mechanisms are used by our organisms to maintain immune 
homeostasis. Without them, over-activation of cytotoxic cells may appear, causing 
tissue damage and organ failure. However, cancer and chronic infections may 
benefit from different suppressive mechanisms. One of the approaches used in 
this study is the combination treatment blocking different inhibitory mechanisms: 
inhibitory receptors and their ligands, as well as Tregs. The depletion of PD-L1, 
Tim3 and Tregs resulted in reduced viral loads (Figure 5.6) and an increased 
production of cytotoxic granula in T cells (Figure 5.7). Distinct studies involving 
combinational treatment by blocking different inhibitory mechanisms exhibit 
beneficial influence on the disease (19). It has been shown that the immune 
checkpoint blockade is a possible, effective way of treating cancer (61-65). 
Combination treatment blocking different checkpoint inhibitors resulted in a 
reduction of tumor size and an enhanced immune response in cancer patients 
(93). Inhibitors of PD-1 and CTLA-4 as a combination treatment were used in a 
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phase 3 clinical trial of melanoma therapy (138), as well as of metastatic renal cell 
carcinoma (160) with promising results. Further promising findings came e.g. from 
the cancer field, where combining radiation therapy with dual checkpoint blockade 
of melanoma (138) resulted in an enhanced T cell response and reversed CD8+ T 
cell exhaustion. Surprisingly, the model of combination therapy by  Treg depletion 
combined with dual blockade of inhibitory receptors presented in this work was 
shown to reduce viral loads and restore CD8+ T cell cytotoxicity during chronic FV 
infection (138). It is worth mentioning that in both of these studies blocking of αPD-
L1 was used as one of the immune checkpoint treatments. Interestingly, the level 
of PD-L1 on the cell surface had an influence on therapy outcome during αCTLA-4 
treatment. When the level of PD-L1 on the cell surface during αCTLA-4 treatment 
combined with radiation of melanoma tumor was high, CD8+ T cell functionality 
was not recovered. However, by addition of αPD-L1 antibody, its CD8+ T cell 
function was further restored (138).  
Finally, for the first time to our knowledge, we were able to show that the 
population of Gr1+ CD11bdim, isolated from mice treated with DT, αPD-L1, αTim3 
expanded during FV infection (Figure 5.11). Proliferation of CD8+ was suppressed 
by a lower number of Gr1+ CD11bdim cells compared to gMDSCs. Thus, these data 
suggest the appearance of a new Gr1+ CD11bdim MDSC subset, and the 
expansion of MDSCs during combination treatment may be a compensatory 
mechanism for blocking other inhibitory mechanisms to prevent tissue damage 
during acute retroviral infection. The newly described Gr1+ CD11bdim population 
will be further characterized. 
The FV infection of mice used in the current study is a good model to analyze 
retroviral infections in general. HIV infection of humans still presents a major threat 
to the world population. Even though current therapies of retroviral infections are 
effective in controlling viral replication, the virus cannot be completely eliminated. 
Therefore, it is important to develop possible immunotherapies of retroviral 
infections. The approach used in this study was focused on one of the inhibitory 
mechanisms that restrict retrovirus-specific immunity: MDSC. It has already been 
shown that MDSCs expand during HIV infection (127, 142). Enhanced numbers of 
MDSCs in patient blood were associated with a chronic progressive phase of HIV 
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infection (110). mMDSCs have been reported to expand in PBMCs from healthy 
volunteers incubated with HIV-1 proteins (gp120 or Tat) or the TLR4 ligand LPS in 
vitro (142). Targeting different subtypes of myeloid cells, including MDSCs, was 
suggested to be a new, promising approach for immunotherapy of HIV (142). 
Consequently, the results of this thesis suggest that MDSCs might be a possible 
target for the future treatment of retroviral infections, providing new important 
information about the interaction between different regulatory mechanisms and 
MDSCs. 
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7. Summary 
A recently observed population of myeloid-derived suppressor cells (MDSCs) 
restrains the T cell immune response by showing robust suppressive activity. The 
inhibitory influence of MDSCs was observed in different tumor diseases. First 
attempts to describe MDSCs in infectious diseases were conducted. Nonetheless, 
the role of these cells during viral infection is not fully understood.  
Friend virus is a good model to study both acute and chronic retroviral infections. 
In the FV model, similar to the Human Immunodeficiency Virus (HIV) or Hepatitis 
C Virus (HCV) infections, cytotoxic virus-specific CD8+ T Lymphocytes (CTLs) 
efficiently control acute virus infections but become exhausted when a chronic 
infection develops.    
The data presented in this thesis evidences the influence of myeloid derived 
suppressor cells on cytotoxic CD8+ T cells during acute Friend Virus infection. Two 
populations of MDSCs, granulocytic MDSCs (gMDSCs) and monocytic MDSCs 
(mMDSCs), are expanding during the late phase of acute FV infection, which may 
be correlated with the CD8+ T cell contraction. Additionally, the in vivo elimination 
of the expanded population of granulocytic MDSCs shows the suppressive 
influence of these cells on CD8+ T cell proliferation and their production of 
cytotoxic granules. This effect may be mediated by several mechanisms, as 
proven in vitro, such as PD-L1, arginase, nitric oxide and CD39. Furthermore, 
possible compensatory interactions between different inhibitory mechanisms, such 
as myeloid derived suppressor cells, T regulatory cells, and inhibitory 
receptors/ligands were observed. Finally, the elimination of two important immune 
regulatory mechanisms after the depletion of T regulatory cells, and blocking of 
PD-L1 and Tim3 resulted in an expansion of myeloid derived suppressor cells with 
appearance of the new CD11bdim population of cells. The newly revealed 
population was showing strong suppressive activity against CD8+ T cells during 
acute retroviral infection.  
Myeloid derived suppressor cells play an important role in the regulation of the 
immune response. Thus, the results presented in this thesis show the inhibitory 
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role of myeloid derived suppressor cells in the Friend virus infection and may be a 
possible target for the immune therapy of retroviral infections. 
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8. Zusammenfassung 
Myeloide Suppressorzellen (MDSCs) wurden vor kurzem auf Grund ihrer 
Suppression von T-Zellen identifiziert. Der inhibitorische Einfluss von MDSCs 
wurde in verschiedenen Tumorerkrankungen beobachtet. Die Funktion dieser 
Zellen während der viralen Infektion ist jedoch bis heute nicht vollständig 
verstanden. 
Das Friend Virus Mausmodell eignet sich sowohl für die Untersuchung der akuten 
als auch der chronischen retroviralen Infektion. Ähnlich wie bei Infektionen mit 
dem Humanen Immundefizienz-Virus (HIV) oder Hepatitis-C-Virus (HCV), 
bekämpfen zytotoxische virus-spezifische CD8+ T-Lymphozyten (CTLs) die akute 
Virusinfektion, wohingegen sie während der chronischen Infektion dysfunktional 
sind.  
Insgesamt wurde in dieser Doktorarbeit der Einfluss von Myeloiden 
Suppressorzellen auf zytotoxische CD8+ T-Zellen während der akuten Friend Virus 
Infektion untersucht. Zwei Populationen von MDSCs, granulozytäre MDSCs 
(gMDSCs) und monocytäre MDSCs (mMDSCs) werden während der späten 
Phase der akuten FV Infektion expandiert, was mit einer CD8+ T-Zell-Kontraktion 
korreliert. Eine Population der MDSCs, die Granulozytären MDSCs, zeigen einen 
suppressiven Einfluss auf die CD8+ T-Zell-Proliferation und die Produktion von 
zytotoxischen Granula in vivo. Dieser Effekt kann durch verschiedene 
Mechanismen modelliert werden, wie beispielsweise PD-L1, Arginase, 
Stickstoffmonoxid oder CD39. Die Interaktion zwischen verschiedenen 
hemmenden Mechanismen, wie Myeloide Suppressorzellen, regulatorischen T-
Zellen und inhibitorischen Rezeptoren und Liganden während der akuten FV 
Infektion wurde beobachtet. Die Elimination von zwei wichtigen 
immunregulatorischen Mechanismen führte nach Depletion der regulatorischen T-
Zellen und der Blockierung von PD-L1 und TIM3 zur Expansion der Myeloiden 
Suppressorzellen und einer neuen, durch CD11bdim charakterisierten Population, 
die starke supprimierende Effekte gegenüber CD8+ T-Zellen zeigt. 
Myeloide Suppressorzellen spielen eine wichtige Rolle bei der Regulation der 
Immunantwort. Die in dieser Arbeit vorgestellten Ergebnisse, d. h. die hemmende 
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Rolle von Myeloide Suppressorzellen während der akuten Friend Virus Infektion, 
können als Ansatz für eine Immuntherapie retroviraler Infektionen verwendet 
werden. 
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10 Appendix 
 
10.1 List of Abbreviations 
 
 
Abbreviations Full name 
5FU 5-Fluorouracil 
˚C Degree Celsius 
µl Microlitre 
ADCC Antibody dependent cell mediated 
cytotoxicity 
AF 700 Alexa Fluor 700 
AF 488 Alexa Fluor 488 
AF 647 Alexa Fluor 647 
AIDS Acquired Immune Deficiency 
Syndrome 
APC Antigen presenting cells 
APC Allophycocyanin 
APC-Cy7 APC-cyanine 7 
Arg Arginase 
B7RP1 B7-Related protein1 
BCL-6 B cell lymphoma 6 
BM Bone marrow 
BSA Bovine Serum Albumin 
BV421 Brilliant violet 421 
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BV605 Brilliant violet 605 
CAD Caspase-activated 
deoxyribonuclease 
cAMP Cyclic adenosine monophosphate 
CD Cluster of differentiation 
CFSE Carboxyfluorescein succinimidyl 
ester 
CTL Cytotoxic T cells 
CTLA-4 Cytotoxic T Lymphocyte Antigen 4 
DC Dendritic cell 
DEREG Depletion of regulatory T cells 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DT Diphtheria toxin 
DTR Diphtheria toxin receptor 
EDTA Etylenadiaminetetraacetic acid 
eF650 eFluor 650 
eF780 eFluor 780 
eF450 eFluor 450 
Env Envelope protein 
FACS Fluorescence Activated Cells 
Scanner (Flow cytometer) 
FASL FAS ligand 
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FCS Fetal Calf Serum 
FITC Fluorescein isothiocyanate 
F-MuLV Friend murine leukemia virus 
Foxp3 Forkhead box P3 
FSC Forward scatter 
FV Friend Virus 
FVD Fixable viable dye 
g Gram 
Gag Group specific antigen 
GATA-3 Gata binding protein 3 
GFP Green fluorescence protein 
gMDSC Granulocytic myeloid derived 
suppressor cell 
Gzm Granzyme 
HBV Hepatitis B Virus 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
HPV Human papillomavirus 
HTLV-1 Human T cell leukemia virus-1 
i.p. Intraperitoneal 
i.v. Intravenous 
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ICOS Inducible costimulatory 
IDO Idoleamine 2,3-dioxygenase 
IFN-γ Interferon gamma 
Ig Immunoglobulin 
IL Interleukin 
iTregs Induced Tregs 
KLRG-1 Killer cell lectin-like receptor 
subfamily G member 1 
l Liter 
LAG-3 Lymphocyte-activation gene 3 
LN Lymph nodes 
L-NMMA NG-Monomethyl-L-arginine, 
monoacetate salt 
 
LTR Long Treminal Repeat 
Mab Monoclonal antibody 
MDSC myeloid derived suppressor cell 
mg Miligram 
MHC Major histocompatibility complex 
ml Mililitre 
mMDSC monocytic myeloid-derived 
suppressor cell 
mRNA Messenger RNA 
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MSV Murine sarcoma virus 
n.s. Non-significant 
NK Natural Killer cells 
Nor-NOHA Nω-hydroxy-nor-Arginine 
NOS Nitric oxide synthase 
Nrp-1 Neuropilin-1 
nTregs Natural Tregs 
PAMPs Pathogen-Associated Molecular 
Patterns 
PBBS Phosphate Buffered Saline, 
containing 1.0 g glucose 
PBS Phosphate Buffered Saline 
PD-1 Programmed cell death 1 
PD-L1 Programmed cell death ligand 1 
PE Phycoerythrin 
PE Cy5 Phycoerythrin-Cyanine 5 
PE Cy7 Phycoerythrin- Cyanine 7 
PerCP Peridinin-chlorophyll-protein 
complex 
PI Propidium iodide 
PMT Photomultiplier tube 
Pol Polymerase 
PRR Pathogen Recognition Receptors 
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RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPMI-1640 Rosewell Park Memorial Institute 
Medium 1640 
RSV Rous sarcoma virus 
s.c. Subcutaneous 
SFFV Spleen focus forming virus 
si Small intestine 
SPF Specific pathogen-free 
SSC Sideward scatter 
STAT Signal Transducer and Activator of 
Transcription 
Tcon Conventional CD4+ T cells 
TCR T cell receptor 
Tetr Tetramer 
TGF-β Transforming Growth Factor-beta 
Th T helper cells 
Tim3 T cell immunoglobulin domain and 
mucin domain-3 
TLR Toll-Like Receptor 
TNFR Tumor necrosis factor receptor 
TNF-α Tumor necrosis factor-alpha 
TRAIL Tumor-necrosis-factor-related 
apoptosis-inducing ligand 
Appendix 
 
 
121 
 
Tregs Regulatory T cells 
 
  
Appendix 
 
 
122 
 
10.2 Figure list 
 
Figure 1.1  Murine granulocytic and monocytic MDSCs  ................................4 
Figure 1.2  Coinhibitory pathways .................................................................. 15 
Figure 1.3  Metabolism of extracellular adenosine and its  
effect of cellular immunity  ........................................................... 16 
Figure 1.4  Retroviral genome ......................................................................... 18 
Figure 1.5  Retroviral life cycle   ...................................................................... 19 
Figure 3.1  Principle of Flow Cytometry   ........................................................ 43 
Figure 3.2  Schematic organization of MHC class I tetramer.  ...................... 47 
Figure 3.3  Gating strategy for murine MDSCs .............................................. 48 
Figure 4.1  Kinetics of the mMDSC and gMDSC response  
during acute FV infection. ............................................................ 54 
Figure 4.2  Kinetics of mMDSCs and gMDSCs infection during  
acute FV infection. ........................................................................ 55 
Figure 4.3  Expression of CD80 and PD-L1 molecules on the 
MDSCs during acute FV infection. ............................................... 56 
Figure 4.4  Expression levels of CD39 and CD73 on MDSCs during 
acute FV infection. ........................................................................ 58 
Figure 4.5  Expression levels of Arg1 and NOS2 in MDSCs are 
upregulated during acute FV infection. ....................................... 59 
Figure 4.6  Schematic of the MDSC depletion during acute FV 
infection in the spleen. ................................................................. 61 
Figure 4.7  Depletion of MDSCs leads to a reduction in viral loads 
during acute FV infection. ............................................................ 63 
Figure 4.8  Depletion of MDSC leads to an expansion of effector 
CD8+ T cells during acute FV infection. ...................................... 64 
Appendix 
 
 
123 
 
Figure 4.9  Increased proliferation of CD8+ T cells after MDSC 
depletion during acute FV infection. ........................................... 65 
Figure 4.10  Upregulation of proinflammatory cytokine expression 
by CD8+ T cells after MDSC depletion during acute FV 
infection. ........................................................................................ 66 
Figure 4.11  Increased production of granzyme B by CD8+ T cells 
after MDSC depletion during acute FV infection. ....................... 67 
Figure 4.12  Depletion of total MDSCs did not affect in vivo 
cytotoxicity of CD8+ T cell ........................................................... 68 
Figure 4.13  Granulocytic myeloid derived suppressor cells 
inhibited CD8+ T cell proliferation. .............................................. 70 
Figure 4.14  Granulocytic myeloid derived suppressor cells 
inhibited GzmB production by CD8+ T cells. .............................. 71 
Figure 4.15  Suppression of nitric oxide and arginase partially 
restored CD8+ T cell proliferation. .............................................. 72 
Figure 4.16  Lack of PD-L1 or CD39 partly restored CD8+ T cell 
proliferation ................................................................................... 74 
Figure 5.1  Tregs expand upon MDSCs depletion in FV-infected 
mice ................................................................................................ 77 
Figure 5.2  Depletion of Tregs led to MDSC expansion in FV-
infected mice ................................................................................. 78 
Figure 5.3  Characterization of MDSCs after Treg depletion during 
acute FV infection. ........................................................................ 79 
Figure 5.4  Combination of gMDSCs and Tregs depletion leads to a 
reduction in viral loads and increased numbers of 
activated virus specific CD8+ T cells. ......................................... 80 
Figure 5.5  Treatment of acute FV infection with αPD-L1, αTim3 
and depletion of Tregs. ................................................................. 82 
Appendix 
 
 
124 
 
Figure 5.6  Depletion of Tregs combined with blocking inhibitory 
receptors leads to reduction of viral loads during acute 
FV infection.................................................................................... 82 
Figure 5.7  CD8+ T cell responses during acute FV infection after 
Treg depletion combined with αPD-L1 and αTim3 
treatment. ....................................................................................... 83 
Figure 5.8  Percentage of CD8+GzmB+ and CD4+GzmB+ T cells 
after Treg depletion combined with αPD-L1 and αTim3 
treatment during FV infection. ..................................................... 84 
Figure 5.9  MDSC expansion after Treg depletion combined with 
αPD-L1 and αTim3 treatment. ...................................................... 86 
Figure 5.10  Characterization of gMDSCs after Tregs depletion 
combined with αPD-L1 and αTim3 treatment. ............................ 87 
Figure 5.11  Newly expanded Gr1+ CD11bdim population 
suppressed CD8+ T cell proliferation. ......................................... 88 
  
Appendix 
 
 
125 
 
10.3 Table list 
 
 
Table 1.1 Strategies of MDSCs Inhibition Under Investigation (144)  ............... 7 
Table 2.1 Buffer and supplemented cell culture media  ................................... 28 
Table 2.2 Characteristics of fluorophores  ........................................................ 29 
Table 2.3 Antibodies  .......................................................................................... 30 
Table 2.4 Staining reagents  ............................................................................... 33 
Table 2.5 Standard kits  ...................................................................................... 34 
Table 2.6 Depletion antibody and treatment reagents  .................................... 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
126 
 
10.4 List of publications: 
 
 
Akhmetzyanova I, Drabczyk M, Neff CP, Gibbert K, Dietze KK, Werner T, et 
al. (2015) PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune 
Escape from CD8+ T Cell Killing. PLoS Pathog 11(10): e1005224. 
doi:10.1371/journal.ppat.1005224 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
127 
 
10.5 Acknowledgements  
 
First and foremost I want to thank Prof. Dr. Ulf Dittmer and Dr. Gennadiy 
Zelinskyy, who made it possible for me to conduct my PhD at the Institute for 
Virology. I want to thank them for the guidance, supervision and support 
throughout all the years.  
 
Special thanks to all my colleagues and graduate friend. I want to thank everyone 
in the group of Prof. Dr. Ulf Dittmer, present and past members (Kathrin, Kirsten, 
Wibke, Ilseyar, Inga, Elisabeth, Camilla, Nadine, Alex, Paul, Jara, Ursula, Delia, 
Max, Tamara, Simone, Sonja, Tanja, Sandra). I would like to specially thank them 
for giving me their full support and help. I especially want to thank Daniela Catrini, 
who was always there for me, for her support and friendship. 
 
I want to thank my friends Steffi and Nicole for the wonderful times in Essen and 
huge support. Furthermore, I want to thank Ania, Asia, Justyna for the good times 
we had and help each time I needed it. 
I owe my deepest gratitude to my husband for the faith, support and 
encouragement.  
 
Lastly, and most importantly, I wish to express my love and gratitude to my 
beloved parents and sister for their unconditional love and understanding, through 
the duration of my time in Essen. 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
128 
 
10.6 Curriculum Vitae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
129 
 
 
